192 results on '"Schwarz TF"'
Search Results
2. A new fully liquid presentation of MenACWY-CRM conjugate vaccine: Results from a multicentre, randomised, controlled, observer-blind study
- Author
-
Vandermeulen, C, Leroux-Roels, I, Vandeleur, J, Staniscia, T, Girard, G, Ferguson, M, Icardi, G, Schwarz, TF, Neville, AM, Nolan, T, Cinquetti, S, Akhund, T, Van Huyneghem, S, Aggravi, M, Kunnel, B, de Wergifosse, B, Di Domenico, GF, Costantini, M, Singh, PV, Fragapane, E, Lattanzi, M, Pellegrini, M, Vandermeulen, C, Leroux-Roels, I, Vandeleur, J, Staniscia, T, Girard, G, Ferguson, M, Icardi, G, Schwarz, TF, Neville, AM, Nolan, T, Cinquetti, S, Akhund, T, Van Huyneghem, S, Aggravi, M, Kunnel, B, de Wergifosse, B, Di Domenico, GF, Costantini, M, Singh, PV, Fragapane, E, Lattanzi, M, and Pellegrini, M
- Abstract
BACKGROUND: The currently licensed quadrivalent MenACWY-CRM conjugate vaccine presentation consists of two vials (lyophilised MenA and liquid MenCWY) to be reconstituted before injection. A new fully liquid formulation in a single vial has been developed to further improve the vaccine presentation. Since the MenA structure is subject to hydrolytic degradation, this study was conducted to compare the immunogenicity and safety of the investigational MenACWY-CRM liquid vaccine with the licensed vaccine. METHODS: In this multicentre, randomised, controlled, observer-blind, phase 2b study, 979 healthy adults were administered a single dose of MenACWY-CRM liquid presentation or the currently licensed MenACWY-CRM vaccine. MenA free saccharide generation was accelerated to approximately 30% in the liquid presentation and MenA polysaccharide O-acetylation was reduced to approximately 40%, according to a controlled procedure. Immunological non-inferiority of the MenACWY-CRM liquid to the licensed vaccine, as measured by human serum bactericidal assay (hSBA) geometric mean titres (GMTs) against MenA 1 month post-vaccination, was the primary study objective. Safety assessment was among the secondary objectives. RESULTS: Immune responses against each serogroup were similar between the two vaccine groups and was non-inferior for MenA. Adjusted hSBA GMTs for MenA were 185.16 and 211.33 for the MenACWY-CRM liquid presentation and currently licensed vaccine presentation, respectively. The between-group ratio of hSBA GMTs for MenA was 0.88, with a two-sided 95% confidence interval lower limit of 0.64, greater than the prespecified non-inferiority margin of 0.5, thus meeting the primary study objective. Both vaccines were well tolerated. No serious adverse events were considered related to vaccination. CONCLUSIONS: The levels of MenA free saccharide and polysaccharide O-acetylation did not affect the immunogenicity of the fully liquid presentation, which was demonstrated to be non-inf
- Published
- 2021
3. Experts' opinion for improving global adolescent vaccination rates: a call to action
- Author
-
Azzari C, Diez-Domingo J, Eisenstein E, Faust SN, Konstantopoulos A, Marshall GS, Rodrigues F, Schwarz TF, and Weil-Olivier C
- Subjects
Preventive healthcare ,Vaccine-preventable diseases ,Vaccination ,Immunization ,Adolescence - Abstract
Worldwide, lifestyle and resource disparities among adolescents contribute to unmet health needs, which have crucial present and future public health implications for both adolescents and broader communities. Risk of infection among adolescents is amplified by biological, behavioral, and environmental factors; however, infectious diseases to which adolescents are susceptible are often preventable with vaccines. Beyond these concerns, there is a lack of knowledge regarding adolescent vaccination and disease risk among parents and adolescents, which can contribute to low vaccine uptake. Promising efforts have been made to improve adolescent vaccination by programs with motivational drivers and comprehensive communication with the public. In May 2017, a multidisciplinary group of experts met in Amsterdam, Netherlands, to discuss adolescent vaccine uptake, as part of an educational initiative called the Advancing Adolescent Health Spring Forum. This article presents consensus opinions resulting from the meeting, which pertain to the burden of vaccine-preventable diseases among adolescents, reasons for low vaccine uptake, and common characteristics of successful strategies for improving adolescent vaccination. Conclusion: There is an urgent "call to action," particularly targeting healthcare providers and public health authorities, for the prioritization of adolescent vaccination as a necessary element of preventive healthcare in this age group.What is Known:center dot Despite increased risk of certain infectious diseases, adolescent vaccination uptake remains low.What is New:center dot Barriers to adolescent vaccine uptake include lack of information regarding vaccines and disease risk, health system inadequacies, and insufficient healthcare follow-up.center dot Successful efforts to improve adolescent vaccine uptake need cohesive leadership and involvement of multiple stakeholders, as well as youth-friendly messaging; healthcare providers and policymakers should prioritize adolescent vaccination and implement proven program strategies to improve adolescent health worldwide.
- Published
- 2020
4. A Bivalent Meningococcal B Vaccine in Adolescents and Young Adults
- Author
-
Ostergaard, L., Vesikari, T., Absalon, J., Beeslaar, J., Ward, B. J., Senders, S., Eiden, J. J., Jansen, K. U., Anderson, A. S., York, L. J., Jones, T. R., Harris, S. L., O'Neill, R., Radley, D., Maansson, R., Pregaldien, J. -L., Ginis, J., Staerke, N. B., Perez, J. L., Belle-Isle, J, Elfassi, E, Fredette, P, Garfield, H, Girard, G, Lachance, P, Adamkova, E, Bartonova, E, Drazan, D, Dvorakova, J, Kosina, P, Kyjonkova, A, Ruzkova, R, Vitousova, E, Ahonen, A, Forsten, A, Karppa, T, Kokko, S, Lagerstrom-Tirri, Pm, Simila, Jk, Adelt, T, Behre, U, Schwarz, Tf, Castiglia, P, Esposito, S, Ferrera, G, Icardi, G, Brzostek, J, Hasiec, B, Konior, R, Pejcz, J, Szymanski, H, Witor, A, Faust, Sn, Finn, Ah, Heath, Pt, Pollard, Aj, Altamirano, Dd, Ashley CT Jr, Bader, Gf, Bauer GH Jr, Block SL Jr, Brandon, Dm, Davis, Mg, Devalle, O, Egelhof, Rh, Essink, Bj, Fouch, Bb, Fox, Bp, Franklin, Er, Garscadden, Ag, Goswami, Up, Gregory, Dm, Helman, Ll, Houchin, Vg, Howard, Ce, Johnson, Ad, Johnston WH Jr, Jordan, Ca, Kimmel, Ma, Klein, Tr, Krilov, Lr, Labarbera, Ap, Labuda JM II, Latiolais, Tg, Lello, Lg, Lewis, Dh, Ley, Ja, London, Al, Martin, Ms, Mcguire, Mr, Mosteller, Vc, Naccarato, Tr, Nassim, Cg, Rey, Mr, Robbins, Ra, Rouse, Kg, Schear, Mj, Senders, Sd, Shepard, Js, Simpson, Mw, Slandzicki, Aj, Slechta, Sb, Tetrick, Ll, Varman, M, Wadsworth LT III, Ware, Db, White, Jh, Wisman PP Jr, Blouin, F, Dionne, M, Dzongowski, P, Heaton, Kj, Langley, Jm, O'Mahony, Mfj, Powell, Cn, Ward, Bj, Ostergaard, Lj, Haapaniemi, Tl, Paassilta, M, Volanen, Ik, Lepich, T, Smukalska, E, Tarczon, I, Tetiurka, Bm, Domingo, Jd, Morato, Av, Riera, Mt, Sanchez, Ca, Torrell, Jmr, Blumenau, J, Campbell, Ng, Cervantes, Ja, Douglas, Wg, Ensz, Dj, Ervin, Je, Fiel, Tc, Fragoso, Vg, Fried, Dl, Gleason, Gp, Green, Sl, Haggag, Az, Johnson, Ct, Khaira, Rs, Kirstein, Jl, Kravitz, Ae, Lederman, Sn, Marcadis, I, Miller, Ve, Moretti, Jm, Pragalos, Aa, Puopolo, Ad, Rubino, J, Seiden, Dj, Sharp, Sc, Sheldon, Ea, Shockey, Gr, Smith, Wb, Stringer, Jc, Strout, Cb, Studdard, He, and Tresser, Njl.
- Subjects
Male ,0301 basic medicine ,Clinical Trial, Phase III ,Hepatitis A vaccine ,Neisseria meningitidis, Serogroup B ,Neisseria meningitidis ,medicine.disease_cause ,bacterial protein ,Group B ,0302 clinical medicine ,Single-Blind Method ,030212 general & internal medicine ,Child ,Phylogeny ,biology ,Immunogenicity ,Bacterial ,General Medicine ,hepatitis A vaccine ,Meningococcus vaccine ,bacterial antigen ,bacterium antibody ,factor H-binding protein, Neisseria meningitidis ,Antibodies, Bacterial ,Intention to Treat Analysis ,Multicenter Study ,Titer ,Randomized Controlled Trial ,factor H-binding protein ,Female ,Antibody ,Adult ,Adolescent ,Fever ,Serogroup B ,030106 microbiology ,Meningococcal Vaccines ,Meningococcal vaccine ,Antibodies ,Young Adult ,03 medical and health sciences ,Bacterial Proteins ,Journal Article ,medicine ,Antigens, Bacterial ,Humans ,Meningococcal Infections ,Antigens ,business.industry ,Immunology ,biology.protein ,Bacterial antigen ,business - Abstract
BACKGROUND: MenB-FHbp is a licensed meningococcal B vaccine targeting factor H-binding protein. Two phase 3 studies assessed the safety of the vaccine and its immunogenicity against diverse strains of group B meningococcus.METHODS: We randomly assigned 3596 adolescents (10 to 18 years of age) to receive MenB-FHbp or hepatitis A virus vaccine and saline and assigned 3304 young adults (18 to 25 years of age) to receive MenB-FHbp or saline at baseline, 2 months, and 6 months. Immunogenicity was assessed in serum bactericidal assays that included human complement (hSBAs). We used 14 meningococcal B test strains that expressed vaccine-heterologous factor H-binding proteins representative of meningococcal B epidemiologic diversity; an hSBA titer of at least 1:4 is the accepted correlate of protection. The five primary end points were the proportion of participants who had an increase in their hSBA titer for each of 4 primary strains by a factor of 4 or more and the proportion of those who had an hSBA titer at least as high as the lower limit of quantitation (1:8 or 1:16) for all 4 strains combined after dose 3. We also assessed the hSBA responses to the primary strains after dose 2; hSBA responses to the 10 additional strains after doses 2 and 3 were assessed in a subgroup of participants only. Safety was assessed in participants who received at least one dose.RESULTS: In the modified intention-to-treat population, the percentage of adolescents who had an increase in the hSBA titer by a factor of 4 or more against each primary strain ranged from 56.0 to 85.3% after dose 2 and from 78.8 to 90.2% after dose 3; the percentages of young adults ranged from 54.6 to 85.6% and 78.9 to 89.7%, after doses 2 and 3, respectively. Composite responses after doses 2 and 3 in adolescents were 53.7% and 82.7%, respectively, and those in young adults were 63.3% and 84.5%, respectively. Responses to the 4 primary strains were predictive of responses to the 10 additional strains. Most of those who received MenB-FHbp reported mild or moderate pain at the vaccination site.CONCLUSIONS: MenB-FHbp elicited bactericidal responses against diverse meningococcal B strains after doses 2 and 3 and was associated with more reactions at the injection site than the hepatitis A virus vaccine and saline. (Funded by Pfizer; ClinicalTrials.gov numbers, NCT01830855 and NCT01352845 ).
- Published
- 2017
5. Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older
- Author
-
Cunningham, A. L., Lal, H., Kovac, M., Chlibek, R., Hwang, S. -J., Diez-Domingo, J., Godeaux, O., Levin, M. J., Mcelhaney, J. E., Puig-Barbera, J., Vanden Abeele, C., Vesikari, T., Watanabe, D., Zahaf, T., Ahonen, A., Athan, E., Barba-Gomez, J. F., Campora, L., De Looze, F., Downey, H. J., Ghesquiere, W., Gorfinkel, I., Korhonen, T., Leung, E., Mcneil, S. A., Oostvogels, L., Rombo, L., Smetana, J., Weckx, L., Yeo, W., Heineman, T. C., Athan, E, Cunningham, Al, de Looze, F, Eizenberg, P, Yeo, W, Avelino-Silva, Tj, Neto, Jl, Santos, Rr, Weckx, L, Zerbini, Ca, Gauthier, Js, Ghesquiere, W, Gorfinkel, I, Mcelhaney, Je, Mcneil, Sa, Toma, A, Chlibek, R, Smetana, J, Poder, A, Ahonen, A, Forsten, A, Karppa, T, Korhonen, T, Seppä, I, Vesikari, T, Esen, M, Schwarz, Tf, Leung, E, Desole, Mg, Icardi, G, Pellegrino, A, Staniscia, T, Volpi, A, Ikematsu, H, Watanabe, D, Choi, Ws, Barba-Gomez, Jf, Mascarenas de Los Santos, A, Tinoco, Jc, Brotons, C, Caso, C, Diez-Domingo, J, Narejos Perez, S, Puig-Barberà, J, Rodriguez de la Pinta ML, Berglund, J, Blom, Kb, Liu, B, Pauksens, K, Rombo, L, Hwang, Sj, Thompson, A, Andrews, C, Jackson Downey, H, Freedman, M, Levin, M, Arbi, Mb, Campora, L, Catteau, G, Curran, D, Godeaux, O, Heineman, Tc, Kovac, M, Lal, H, Marion, S, Oostvogels, L, Oujaa, M, Ravault, S, Abeele, Cv, Vastiau, I, Zahaf, T, Junqueira, T, Berndtsson Blom, K, Downey, H, Rodriguez, Ml, Zerbini, C, Heineman, T, Levin, Mj, Puig, J, and Heineman, Tc.
- Subjects
Male ,Risk ,0301 basic medicine ,Subunit ,medicine.medical_specialty ,Herpes Zoster Vaccine ,Neuralgia, Postherpetic ,Kaplan-Meier Estimate ,Placebo ,Herpes Zoster ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,Double-Blind Method ,Randomized controlled trial ,law ,Internal medicine ,80 and over ,medicine ,Humans ,030212 general & internal medicine ,Aged ,Aged, 80 and over ,Vaccines ,business.industry ,Postherpetic neuralgia ,General Medicine ,Middle Aged ,medicine.disease ,Vaccine efficacy ,Surgery ,Clinical trial ,030104 developmental biology ,Female ,Vaccines, Subunit ,Neuralgia ,Zoster vaccine ,Postherpetic ,business ,medicine.drug - Abstract
BACKGROUND A trial involving adults 50 years of age or older (ZOE-50) showed that the herpes zoster subunit vaccine (HZ/su) containing recombinant varicella-zoster virus glycoprotein E and the AS01(B) adjuvant system was associated with a risk of herpes zoster that was 97.2% lower than that associated with placebo. A second trial was performed concurrently at the same sites and examined the safety and efficacy of HZ/su in adults 70 years of age or older (ZOE-70). METHODS This randomized, placebo-controlled, phase 3 trial was conducted in 18 countries and involved adults 70 years of age or older. Participants received two doses of HZ/su or placebo (assigned in a 1: 1 ratio) administered intramuscularly 2 months apart. Vaccine efficacy against herpes zoster and postherpetic neuralgia was assessed in participants from ZOE-70 and in participants pooled from ZOE-70 and ZOE-50. RESULTS In ZOE-70, 13,900 participants who could be evaluated (mean age, 75.6 years) received either HZ/su (6950 participants) or placebo (6950 participants). During a mean follow-up period of 3.7 years, herpes zoster occurred in 23 HZ/su recipients and in 223 placebo recipients (0.9 vs. 9.2 per 1000 person-years). Vaccine efficacy against herpes zoster was 89.8% (95% confidence interval [CI], 84.2 to 93.7; P
- Published
- 2016
6. Erkrankungen durch humane Papillomviren
- Author
-
Schwarz Tf and Zollner U
- Subjects
Cervical cancer ,medicine.medical_specialty ,business.industry ,Gardasil ,Immunogenicity ,virus diseases ,General Medicine ,Cervical intraepithelial neoplasia ,medicine.disease ,Dermatology ,female genital diseases and pregnancy complications ,Vaccination ,medicine ,Papilloma ,Cervarix ,Young adult ,business ,medicine.drug - Abstract
Human papilloma viruses are responsible for a large number of benign and malignant lesions of the skin. HPV 6 and 11 cause up to 90 % of condylomata. Almost each cervical cancer is associated with HPV. HPV 16 und 18 induce up to 70 % of cervical neoplasias. The vaccination against HPV is internationally implemented and should be applied to young girls aged 12 to 17 according to STIKO criteria. The vaccination may reduce the rate of cervical cancer by 70 % and the rate of cervical intraepithelial neoplasia by 50 %. Many studies demonstrated the efficacy and safetyness of both vaccines. Gardasil (®) offers protection against HPV 6, 11, 16 and 18, Cervarix (®) against HPV 16 and 18. Protection against condylomata is offered by the quadrivalent vaccine in 90 %. The bivalent vaccine has demonstrated type-specific protection against the five most frequent cancer inducing types (16, 18, 31, 33, 45). The production of VLPs is an innovative technology. A comparison of both vaccines, Cervarix (®) and Gardasil (®), showed a higher immunogenicity for Cervarix (®). In Germany the immunization rates are still low comparing to other countries. As a method for secondary prevention of cervical cancer the PAP smear is still an effective method.
- Published
- 2011
7. Hämatologische Bedeutung der Parvovirus-B19-Infektion
- Author
-
Jäger G and Schwarz Tf
- Subjects
biology ,business.industry ,Parvovirus ,Medicine ,General Medicine ,business ,biology.organism_classification ,Virology - Published
- 2008
8. Tropische Viruserkrankungen
- Author
-
Schwarz Tf, Meyer Cg, and May J
- Subjects
Text mining ,business.industry ,General Medicine ,Computational biology ,Biology ,business - Published
- 2008
9. Häufigkeit der Parvoviras-B19-Infektionen: Seroepidemiologische Untersuchungen
- Author
-
Schwarz Tf, Roggendorf M, and Friedrich Deinhardt
- Subjects
medicine.medical_specialty ,biology ,Erythema ,Parvovirus ,business.industry ,Incidence (epidemiology) ,General Medicine ,Seroepidemiologic Studies ,biology.organism_classification ,medicine.disease ,Rash ,Asymptomatic ,Enteritis ,Internal medicine ,medicine ,medicine.symptom ,business ,Erythroblastosis fetalis - Abstract
Anti-B19-IgG antibodies were tested for by the ELISA method in 768 sera, 76 from children and juveniles, aged 1-15 years, attending the Outpatients Department of the Children's Clinic, University of Munich, and 692 from persons, aged 18-68 years, attending the blood donor service of the Bavarian Red Cross in Munich. 38.4% of sera were positive, with a significant difference between men and women (32.5% vs. 47.5%, P less than or equal to 0.01). A fresh B19 infection was present in 42 subjects by demonstrating anti-B19-IgM in the ELISA test. The sera came from seven patients with infectious erythema, 26 with skin rash of uncertain cause, two with erythroblastosis fetalis, two with enteritis, one with transitory anaemia, one with juvenile polyarthritis, one with lymphadenitis and arthralgia, and two with an asymptomatic course. Viral B19-DNA was demonstrated by nucleic acid hybridization in a blood unit from an asymptomatic blood donor and in amniotic fluid in a case of erythroblastosis fetalis.
- Published
- 2008
10. Prior human papillomavirus-16/18 AS04-adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy: Post-hoc analysis from a randomized controlled trial
- Author
-
Garland, SM, Paavonen, J, Jaisamrarn, U, Naud, P, Salmeron, J, Chow, S-N, Apter, D, Castellsague, X, Teixeira, JC, Skinner, SR, Hedrick, J, Limson, G, Schwarz, TF, Poppe, WAJ, Xavier Bosch, F, de Carvalho, NS, Germar, MJV, Peters, K, Rowena Del Rosario-Raymundo, M, Catteau, G, Descamps, D, Struyf, F, Lehtinen, M, Dubin, G, Garland, SM, Paavonen, J, Jaisamrarn, U, Naud, P, Salmeron, J, Chow, S-N, Apter, D, Castellsague, X, Teixeira, JC, Skinner, SR, Hedrick, J, Limson, G, Schwarz, TF, Poppe, WAJ, Xavier Bosch, F, de Carvalho, NS, Germar, MJV, Peters, K, Rowena Del Rosario-Raymundo, M, Catteau, G, Descamps, D, Struyf, F, Lehtinen, M, and Dubin, G
- Abstract
We evaluated the efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in preventing HPV-related disease after surgery for cervical lesions in a post-hoc analysis of the PApilloma TRIal against Cancer In young Adults (PATRICIA; NCT00122681). Healthy women aged 15-25 years were randomized (1:1) to receive vaccine or control at months 0, 1 and 6 and followed for 4 years. Women were enrolled regardless of their baseline HPV DNA status, HPV-16/18 serostatus, or cytology, but excluded if they had previous or planned colposcopy. The primary and secondary endpoints of PATRICIA have been reported previously; the present post-hoc analysis evaluated efficacy in a subset of women who underwent an excisional procedure for cervical lesions after vaccination. The main outcome was the incidence of subsequent HPV-related cervical intraepithelial neoplasia grade 2 or greater (CIN2+) 60 days or more post-surgery. Other outcomes included the incidence of HPV-related CIN1+, and vulvar or vaginal intraepithelial neoplasia (VIN/VaIN) 60 days or more post-surgery. Of the total vaccinated cohort of 18,644 women (vaccine = 9,319; control = 9,325), 454 (vaccine = 190, control = 264) underwent an excisional procedure during the trial. Efficacy 60 days or more post-surgery for a first lesion, irrespective of HPV DNA results, was 88.2% (95% CI: 14.8, 99.7) against CIN2+ and 42.6% (-21.1, 74.1) against CIN1+. No VIN was reported and one woman in each group had VaIN2+ 60 days or more post-surgery. Women who undergo surgical therapy for cervical lesions after vaccination with the HPV-16/18 vaccine may continue to benefit from vaccination, with a reduced risk of developing subsequent CIN2+.
- Published
- 2016
11. Risk of Newly Detected Infections and Cervical Abnormalities in Women Seropositive for Naturally Acquired Human Papillomavirus Type 16/18 Antibodies: Analysis of the Control Arm of PATRICIA
- Author
-
Castellsague, X, Naud, P, Chow, S-N, Wheeler, CM, Germar, MJV, Lehtinen, M, Paavonen, J, Jaisamrarn, U, Garland, SM, Salmeron, J, Apter, D, Kitchener, H, Teixeira, JC, Skinner, SR, Limson, G, Szarewski, A, Romanowski, B, Aoki, FY, Schwarz, TF, Poppe, WAJ, Xavier Bosch, F, de Carvalho, NS, Peters, K, Tjalma, WAA, Safaeian, M, Raillard, A, Descamps, D, Struyf, F, Dubin, G, Rosillon, D, Baril, L, Castellsague, X, Naud, P, Chow, S-N, Wheeler, CM, Germar, MJV, Lehtinen, M, Paavonen, J, Jaisamrarn, U, Garland, SM, Salmeron, J, Apter, D, Kitchener, H, Teixeira, JC, Skinner, SR, Limson, G, Szarewski, A, Romanowski, B, Aoki, FY, Schwarz, TF, Poppe, WAJ, Xavier Bosch, F, de Carvalho, NS, Peters, K, Tjalma, WAA, Safaeian, M, Raillard, A, Descamps, D, Struyf, F, Dubin, G, Rosillon, D, and Baril, L
- Abstract
BACKGROUND: We examined risk of newly detected human papillomavirus (HPV) infection and cervical abnormalities in relation to HPV type 16/18 antibody levels at enrollment in PATRICIA (Papilloma Trial Against Cancer in Young Adults; NCT00122681). METHODS: Using Poisson regression, we compared risk of newly detected infection and cervical abnormalities associated with HPV-16/18 between seronegative vs seropositive women (15-25 years) in the control arm (DNA negative at baseline for the corresponding HPV type [HPV-16: n = 8193; HPV-18: n = 8463]). RESULTS: High titers of naturally acquired HPV-16 antibodies and/or linear trend for increasing antibody levels were significantly associated with lower risk of incident and persistent infection, atypical squamous cells of undetermined significance or greater (ASCUS+), and cervical intraepithelial neoplasia grades 1/2 or greater (CIN1+, CIN2+). For HPV-18, although seropositivity was associated with lower risk of ASCUS+ and CIN1+, no association between naturally acquired antibodies and infection was demonstrated. Naturally acquired HPV-16 antibody levels of 371 (95% confidence interval [CI], 242-794), 204 (95% CI, 129-480), and 480 (95% CI, 250-5756) EU/mL were associated with 90% reduction of incident infection, 6-month persistent infection, and ASCUS+, respectively. CONCLUSIONS: Naturally acquired antibodies to HPV-16, and to a lesser extent HPV-18, are associated with some reduced risk of subsequent infection and cervical abnormalities associated with the same HPV type.
- Published
- 2014
12. Risk of first cervical HPV infection and pre-cancerous lesions after onset of sexual activity: analysis of women in the control arm of the randomized, controlled PATRICIA trial
- Author
-
Castellsague, X, Paavonen, J, Jaisamrarn, U, Wheeler, CM, Skinner, SR, Lehtinen, M, Naud, P, Chow, S-N, Del Rosario-Raymundo, MR, Teixeira, JC, Palmroth, J, de Carvalho, NS, Germar, MJV, Peters, K, Garland, SM, Szarewski, A, Poppe, WAJ, Romanowski, B, Schwarz, TF, Tjalma, WAA, Bosch, FX, Bozonnat, M-C, Struyf, F, Dubin, G, Rosillon, D, Baril, L, Castellsague, X, Paavonen, J, Jaisamrarn, U, Wheeler, CM, Skinner, SR, Lehtinen, M, Naud, P, Chow, S-N, Del Rosario-Raymundo, MR, Teixeira, JC, Palmroth, J, de Carvalho, NS, Germar, MJV, Peters, K, Garland, SM, Szarewski, A, Poppe, WAJ, Romanowski, B, Schwarz, TF, Tjalma, WAA, Bosch, FX, Bozonnat, M-C, Struyf, F, Dubin, G, Rosillon, D, and Baril, L
- Abstract
BACKGROUND: More information is needed about time between sexual initiation and human papillomavirus (HPV) infection and development of cervical precancer. METHODS: The objectives were to investigate the time between first sexual activity and detection of first cervical HPV infection or development of first cervical intraepithelial neoplasia (CIN), and associated factors in women from the double-blind, multinational, 4-year PATRICIA trial. PATRICIA enroled women aged 15-25 years with no more than 6 lifetime sexual partners. Women were randomized 1:1 to the HPV-16/18 AS04-adjuvanted vaccine or to control, but only women from the control arm who began sexual intercourse during the study or within 6 months before enrolment, and had no HPV infection detected before the recorded date of their first sexual intercourse, were included in the present analysis. The time between onset of sexual activity and detection of the first cervical HPV infection or development of the first CIN lesion was analyzed using Kaplan-Meier and univariate and multivariable Cox proportional-hazards models. RESULTS: A total of 9337 women were enroled in the control arm of PATRICIA of whom 982 fulfilled the required inclusion criteria for analysis. A cumulative total of 28%, 44%, and 62% of the subjects had HPV infection within 12, 24, and 48 months, respectively. The overall incidence rate was 27.08 per 100 person-years. The most common oncogenic types associated with 6-month persistent infection were HPV-16 (incidence rate: 2.74 per 100 person-years), HPV-51 (2.70), HPV-52 (1.66), HPV-66 (1.14), and HPV-18 (1.09). Increased infection risk was associated with more lifetime sexual partners, being single, Chlamydia trachomatis history, and duration of hormone use. CIN1+ and CIN2+ lesions were most commonly associated with HPV-16, with an overall incidence rate of 1.87 and 1.07 per 100 person-years, respectively. Previous cervical HPV infection was most strongly associated with CIN development. CONCL
- Published
- 2014
13. Productive infection of in vitro generated haemopoietic progenitor cells from normal human adult peripheral blood with parvovirus B19: studies by morphology, immunocytochemistry, flow-cytometry and DNA-hybridization
- Author
-
Herrad Baurmann, Albrecht von Brunn, Stefan Serke, Barbara Hottenträger, D. Huhn, Michael Roggendorf, Friedrich Deinhardt, Andreas Kirsch, and Schwarz Tf
- Subjects
Time Factors ,viruses ,Peripheral blood mononuclear cell ,Parvoviridae ,Flow cytometry ,Immunoenzyme Techniques ,Parvoviridae Infections ,Antigen ,hemic and lymphatic diseases ,medicine ,Humans ,Progenitor cell ,Cells, Cultured ,Interleukin 3 ,biology ,medicine.diagnostic_test ,Parvovirus ,Nucleic Acid Hybridization ,virus diseases ,Hematology ,Flow Cytometry ,Hematopoietic Stem Cells ,biology.organism_classification ,Molecular biology ,medicine.anatomical_structure ,Cell culture ,DNA, Viral ,Bone marrow - Abstract
Parvovirus B19 exerts a highly selective cytopathic effect on erythroid progenitor cells. Studies so far on the pathogenesis of B19-infection have been performed using bone marrow samples providing large amounts of erythroid progenitor cells. Extensive study, however, has been hampered by the limited access to bone marrow samples. We have designed a liquid culture method allowing the generation of large numbers of erythroid progenitor cells, initiating cultures with CD3- and CD14-poor peripheral blood mononuclear cells. Following a 12 d preincubation in liquid cultures containing recombinant human interleukin 3 (rhIl-3) and recombinant human erythropoietin (rhEpo), cells harvested from the liquid cultures were exposed to B19-containing plasma, followed by a further cultivation in liquid culture for up to 96 h. Cells expressing the CD13 and the glycophorin A (GlyA) antigens, respectively, were monitored sequentially by flow-cytometry, demonstrating a selective inhibition of GlyA-positive cells following B19-inoculation. Typical morphological changes were observed on cytocentrifuge-spots, and typical giant-cells were identified as staining for GlyA. Productive infection by B19 was demonstrable, as B19-DNA increased by about x 100 after 72 h of culture. The liquid culture method generating erythroid target cells for effective infection by B19 virus promises to be a useful and easily accessible tool for further research on B19 infection of haemopoietic cells.
- Published
- 1991
14. Natural History of Progression of HPV Infection to Cervical Lesion or Clearance: Analysis of the Control Arm of the Large, Randomised PATRICIA Study
- Author
-
Cameron, DW, Jaisamrarn, U, Castellsague, X, Garland, SM, Naud, P, Palmroth, J, Rowena Del Rosario-Raymundo, M, Wheeler, CM, Salmeron, J, Chow, S-N, Apter, D, Teixeira, JC, Skinner, SR, Hedrick, J, Szarewski, A, Romanowski, B, Aoki, FY, Schwarz, TF, Poppe, WAJ, Bosch, FX, de Carvalho, NS, Germar, MJ, Peters, K, Paavonen, J, Bozonnat, M-C, Descamps, D, Struyf, F, Dubin, GO, Rosillon, D, Baril, L, Cameron, DW, Jaisamrarn, U, Castellsague, X, Garland, SM, Naud, P, Palmroth, J, Rowena Del Rosario-Raymundo, M, Wheeler, CM, Salmeron, J, Chow, S-N, Apter, D, Teixeira, JC, Skinner, SR, Hedrick, J, Szarewski, A, Romanowski, B, Aoki, FY, Schwarz, TF, Poppe, WAJ, Bosch, FX, de Carvalho, NS, Germar, MJ, Peters, K, Paavonen, J, Bozonnat, M-C, Descamps, D, Struyf, F, Dubin, GO, Rosillon, D, and Baril, L
- Abstract
BACKGROUND: The control arm of PATRICIA (PApilloma TRIal against Cancer In young Adults, NCT00122681) was used to investigate the risk of progression from cervical HPV infection to cervical intraepithelial neoplasia (CIN) or clearance of infection, and associated determinants. METHODS AND FINDINGS: Women aged 15-25 years were enrolled. A 6-month persistent HPV infection (6MPI) was defined as detection of the same HPV type at two consecutive evaluations over 6 months and clearance as ≥2 type-specific HPV negative samples taken at two consecutive intervals of approximately 6 months following a positive sample. The primary endpoint was CIN grade 2 or greater (CIN2+) associated with the same HPV type as a 6MPI. Secondary endpoints were CIN1+/CIN3+ associated with the same HPV type as a 6MPI; CIN1+/CIN2+/CIN3+ associated with an infection of any duration; and clearance of infection. The analyses included 4825 women with 16,785 infections (3363 women with 6902 6MPIs). Risk of developing a CIN1+/CIN2+/CIN3+ associated with same HPV type as a 6MPI varied with HPV type and was significantly higher for oncogenic versus non-oncogenic types. Hazard ratios for development of CIN2+ were 10.44 (95% CI: 6.96-15.65), 9.65 (5.97-15.60), 5.68 (3.50-9.21), 5.38 (2.87-10.06) and 3.87 (2.38-6.30) for HPV-16, HPV-33, HPV-31, HPV-45 and HPV-18, respectively. HPV-16 or HPV-33 6MPIs had ~25-fold higher risk for progression to CIN3+. Previous or concomitant HPV infection or CIN1+ associated with a different HPV type increased risk. Of the different oncogenic HPV types, HPV-16 and HPV-31 infections were least likely to clear. CONCLUSIONS: Cervical infections with oncogenic HPV types increased the risk of CIN2+ and CIN3+. Previous or concomitant infection or CIN1+ also increased the risk. HPV-16 and HPV-33 have by far the highest risk of progression to CIN3+, and HPV-16 and HPV-31 have the lowest chance of clearance.
- Published
- 2013
15. Efficacy of the HPV-16/18 AS04-Adjuvanted Vaccine Against Low-Risk HPV Types (PATRICIA Randomized Trial): An Unexpected Observation
- Author
-
Szarewski, A, Skinner, SR, Garland, SM, Romanowski, B, Schwarz, TF, Apter, D, Chow, S-N, Paavonen, J, Del Rosario-Raymundo, MR, Teixeira, JC, De Carvalho, NS, Castro-Sanchez, M, Castellsague, X, Poppe, WAJ, De Sutter, P, Huh, W, Chatterjee, A, Tjalma, WA, Ackerman, RT, Martens, M, Papp, KA, Bajo-Arenas, J, Harper, DM, Torne, A, David, M-P, Struyf, F, Lehtinen, M, Dubin, G, Szarewski, A, Skinner, SR, Garland, SM, Romanowski, B, Schwarz, TF, Apter, D, Chow, S-N, Paavonen, J, Del Rosario-Raymundo, MR, Teixeira, JC, De Carvalho, NS, Castro-Sanchez, M, Castellsague, X, Poppe, WAJ, De Sutter, P, Huh, W, Chatterjee, A, Tjalma, WA, Ackerman, RT, Martens, M, Papp, KA, Bajo-Arenas, J, Harper, DM, Torne, A, David, M-P, Struyf, F, Lehtinen, M, and Dubin, G
- Abstract
BACKGROUND: Public Health England has reported a decrease of up to 20.8% in new diagnoses of external genital warts (GWs) among women aged <19 years since the national vaccination program with the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine began in 2008. A post hoc analysis of the phase III PATRICIA (PApilloma TRIal against Cancer In young Adults) trial (NCT00122681) was performed to ascertain whether protection against low-risk HPV types was apparent. METHODS: Vaccine efficacy (VE) at 48 months was assessed against 6-month persistent infection (6MPI) with low-risk HPV types in the total vaccinated cohort (TVC) and in the TVC naive (for 25 HPV types tested) populations. RESULTS: In the TVC naive cohort, VE against 6MPI (95% confidence interval) was 34.5% (11.3 to 51.8) for HPV-6/11, 34.9% (9.1 to 53.7) for HPV-6, 30.3% (-45.0 to 67.5) for HPV-11, and 49.5% (21.0 to 68.3) for HPV-74. CONCLUSIONS: The HPV-16/18 AS04-adjuvanted vaccine appears to have moderate efficacy against persistent infections with a number of low-risk HPV types (HPV-6/11/74), which are responsible for the majority of external GWs, and recently, antibody and cell-mediated immune response to HPV-6/11 have been observed. These findings may help to explain the decrease in external GW diagnoses seen in England.
- Published
- 2013
16. Prevalence and risk factors for cervical HPV infection and abnormalities in young adult women at enrolment in the multinational PATRICIA trial
- Author
-
Bahmanyar, ER, Paavonen, J, Naud, P, Salmeron, J, Chow, S-N, Apter, D, Kitchener, H, Castellsague, X, Teixeira, JC, Skinner, SR, Jaisamrarn, U, Limson, GA, Garland, SM, Szarewski, A, Romanowski, B, Aoki, F, Schwarz, TF, Poppe, WAJ, De Carvalho, NS, Harper, DM, Bosch, FX, Raillard, A, Descamps, D, Struyf, F, Lehtinen, M, Dubin, G, Bahmanyar, ER, Paavonen, J, Naud, P, Salmeron, J, Chow, S-N, Apter, D, Kitchener, H, Castellsague, X, Teixeira, JC, Skinner, SR, Jaisamrarn, U, Limson, GA, Garland, SM, Szarewski, A, Romanowski, B, Aoki, F, Schwarz, TF, Poppe, WAJ, De Carvalho, NS, Harper, DM, Bosch, FX, Raillard, A, Descamps, D, Struyf, F, Lehtinen, M, and Dubin, G
- Abstract
OBJECTIVE: We evaluated baseline data from the PApilloma TRIal against Cancer In young Adults (PATRICIA; NCT00122681) on the association between behavioral risk factors and HPV infection and cervical abnormalities. METHODS: Women completed behavioral questionnaires at baseline. Prevalence of HPV infection and cervical abnormalities (detected by cytological or histological procedures) and association with behavioral risk factors were analyzed by univariate and stepwise multivariable logistic regressions. RESULTS: 16782 women completed questionnaires. Among 16748 women with data for HPV infection, 4059 (24.2%) were infected with any HPV type. Among 16757 women with data for cytological abnormalities, 1626 (9.7%) had a cytological abnormality, of whom 1170 (72.0%) were infected with at least one oncogenic HPV type including HPV-16 (22.7%) and HPV-18 (9.3%). Multivariable analysis (adjusted for age and region, N=14404) showed a significant association between infection with any HPV type and not living with a partner, smoking, age <15 years at first sexual intercourse, higher number of sexual partners during the past 12 months, longer duration of hormonal contraception and history of sexually transmitted infection (STI). For cervical abnormalities, only history of STI (excluding Chlamydia trachomatis) remained significant in the multivariable analysis after adjusting for HPV infection. CONCLUSIONS: Women reporting 3+ sexual partners in the past 12 months had the highest risk of HPV infection at baseline. HPV infection was the main risk factor for cervical abnormalities, and history of STIs excluding Chlamydia trachomatis increased risk to a lesser extent. Although behavioral factors can influence risk, all sexually active women are susceptible to HPV infection.
- Published
- 2012
17. Acute parvovirus B19 infection mimicking myelodysplastic syndrome of the bone marrow
- Author
-
Michael Roggendorf, D Huhn, S Serke, Herrad Baurmann, J Oertel, and Schwarz Tf
- Subjects
Adult ,Pathology ,medicine.medical_specialty ,Erythema Infectiosum ,Hereditary spherocytosis ,Diagnosis, Differential ,Bone Marrow ,hemic and lymphatic diseases ,Internal medicine ,medicine ,Humans ,Acute leukemia ,Hematology ,biology ,Parvovirus ,business.industry ,virus diseases ,General Medicine ,Hyperplasia ,medicine.disease ,biology.organism_classification ,Pancytopenia ,Red blood cell ,medicine.anatomical_structure ,Myelodysplastic Syndromes ,Immunology ,Female ,Bone marrow ,business - Abstract
A 36-year-old, previously healthy woman was referred to our institution with pancytopenia and splenomegaly for suspected acute leukemia. Bone marrow aspiration showed marked dysplastic changes, excess of blasts, and only spurious red blood cell precursors. Action was taken to prepare allogeneic bone marrow transplantation from an HLA identical sibling for myelodysplastic syndrome. Repeat cytological examination of the bone marrow revealed striking hyperplasia of the red cell line with presence of abnormal giant proerythroblasts. Acute parvovirus B19 infection was suspected and confirmed by detection of anti-B19 IgM and B19 DNA. The underlying disease for this transient aplastic crisis was a formerly unknown hereditary spherocytosis.
- Published
- 1992
18. Replication of parvovirus B19 in hematopoietic progenitor cells generated in vitro from normal human peripheral blood
- Author
-
Barbara Hottenträger, Dieter Huhn, A. von Brunn, Friedrich Deinhardt, Wilhelm Stolz, S Serke, Schwarz Tf, A Kirsch, Michael Roggendorf, and H Baurmann
- Subjects
viruses ,Immunology ,Enzyme-Linked Immunosorbent Assay ,Virus Replication ,Microbiology ,Virus ,Viral Proteins ,Virology ,hemic and lymphatic diseases ,medicine ,Parvovirus B19, Human ,Humans ,Cells, Cultured ,Parvoviridae ,biology ,Parvovirus ,DNA replication ,virus diseases ,biology.organism_classification ,Hematopoietic Stem Cells ,Molecular biology ,In vitro ,Molecular Weight ,Blotting, Southern ,Kinetics ,Blood ,Viral replication ,Cell culture ,Erythropoietin ,Insect Science ,DNA, Viral ,medicine.drug ,Research Article - Abstract
Erythroid progenitor cells generated in vitro from peripheral human blood in the presence of interleukin-3 and erythropoietin were infected with human parvovirus B19. B19 virus DNA replication was highest 48 to 72 h after infection, and maximum levels of B19 virus proteins were detected in culture supernatants at 72 to 96 h after infection. B19 virus propagated in vitro was infectious. This cell culture system with peripheral blood cells facilitates studies in vitro of B19 virus replication.
- Published
- 1992
19. PIN19 A COST-EFFECTIVENESS ANALYSIS OF A PROPHYLACTIC CERVICAL CANCERVACCINE IN GERMANY: RESULTS FROM A HEALTH ECONOMIC MODEL
- Author
-
Hammerschmidt, T, primary, Siebert, U, additional, Schwarz, TF, additional, Schneider, A, additional, Rogoza, RM, additional, Ferko, N, additional, and Welte, R, additional
- Published
- 2007
- Full Text
- View/download PDF
20. Einfluss des Alters bei Impfung auf die langfristigen Effekte einer Impfung gegen Zervixkarzinom
- Author
-
Schneider, A, primary, Schwarz, TF, additional, Hammerschmidt, T, additional, Rogoza, R, additional, Ferko, N, additional, and Siebert, U, additional
- Published
- 2007
- Full Text
- View/download PDF
21. Acute obstructive respiratory diseases in infants and children associated with parvovirus B19 infection
- Author
-
Ballke Eh, Michael Roggendorf, Siegfried Wiersbitzky, Wiersbitzky H, Friedrich Deinhardt, Roswitha Bruns, and Schwarz Tf
- Subjects
Microbiology (medical) ,Male ,Pediatrics ,medicine.medical_specialty ,biology ,business.industry ,Parvovirus ,Erythema Infectiosum ,Infant ,General Medicine ,biology.organism_classification ,Respiration Disorders ,Infectious Diseases ,Child, Preschool ,medicine ,Humans ,Female ,Respiratory system ,business - Published
- 1991
22. Einfluss einer Impfung gegen humane Papillomviren auf die Inzidenz und Mortalität des Zervixkarzinoms in Deutschland
- Author
-
Siebert, U, primary, Bernard, L, additional, Schwarz, TF, additional, Hammerschmidt, T, additional, and Schneider, A, additional
- Published
- 2006
- Full Text
- View/download PDF
23. Vorgehen und Kosten bei der Abklärung und Behandlung unklarer und auffälliger zytologischer Befunde des Pap-Abstrichs im Rahmen der Krebsfrüherkennungsuntersuchungen
- Author
-
Schneider, A, primary, Schwarz, TF, additional, Hammerschmidt, T, additional, Rash, RM, additional, and Siebert, U, additional
- Published
- 2006
- Full Text
- View/download PDF
24. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine coadministered with combined diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine to girls and young women.
- Author
-
Garcia-Sicilia J, Schwarz TF, Carmona A, Peters K, Malkin J, Tran PM, Behre U, Iturbe EB, Catteau G, Thomas F, Dobbelaere K, Descamps D, Dubin G, and HPV Vaccine Adolescent Study Investigators Network
- Abstract
PURPOSE: Many countries recommend human papillomavirus (HPV) vaccination in female adolescents at an age when other vaccines are routinely administered. This open, randomized, multicenter study (108464/NCT00426361) evaluated coadministration of HPV-16/18 AS04-adjuvanted vaccine with diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine (dTpa-IPV). METHODS: Healthy females aged 10-18 years were randomized to receive HPV vaccine at months 0, 1, and 6 (n = 248), HPV vaccine coadministered with dTpa-IPV at month 0 and HPV vaccine at months 1 and 6 (n = 255), or dTpa-IPV at month 0 followed by HPV vaccine at months 1, 2, and 7 (n = 248). Immunogenicity was evaluated at months 0, 1, and 7 or 8 (depending on group). Vaccine reactogenicity and safety were also assessed. RESULTS: Coadministered dTpa-IPV and HPV vaccine was noninferior to dTpa-IPV alone in terms of seroprotection against diphtheria (99.2% and 100%), tetanus (100% and 100%) and poliovirus types 1, 2, and 3 (> or = 99.6%), and geometric mean antibody concentrations (ELISA Units/mL) for pertussis toxoid (84 vs. 75), filamentous hemagglutinin (612 and 615) and pertactin (426 and 360) at month 1. Coadministered dTpa-IPV and HPV vaccine was noninferior to HPV vaccine alone in terms of seroconversion rates for HPV-16 (99.5% and 100%) and HPV-18 (99.5% and 100%) and geometric mean antibody titers (ELISA Units/mL) for HPV-16 (15,608 and 18,965) and HPV-18 (6,597 and 6,902) at month 7. Coadministration was generally well tolerated. The reactogenicity of dTpa-IPV and the first dose of HPV vaccine was similar. CONCLUSIONS: Results from this study support coadministration of the HPV-16/18 AS04-adjuvanted vaccine with dTpa-IPV vaccine in females aged 10-18 years. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
25. Clinical update of the AS04-adjuvanted human papillomavirus-16/18 cervical cancer vaccine, Cervarix®.
- Author
-
Schwarz TF
- Abstract
Persistent infection with human papillomavirus (HPV) is a necessary cause of cervical cancer, resulting annually in 274,000 deaths worldwide. Two prophylactic HPV vaccines are licensed in >100 countries, and immunization programs in young, adolescent girls have been widely implemented. HPV-16/18 AS04-adjuvanted vaccine (Cervarix; GlaxoSmithKline Biologicals, Rixensart, Belgium) has demonstrated type-specific protection against the five most frequent cancer-causing types (16, 18, 31, 33, and 45) that are responsible for 82% of invasive cervical cancers globally. Cervarix has demonstrated efficacy against HPV-45, which is the third most common HPV type in cervical cancer and adenocarcinoma. Final results of a large phase 3 trial recently showed Cervarix substantially reduced the overall burden of cervical precancerous lesions (cervical intraepithelial neoplasia 2+) by 70.2% in an HPV-naïve population approximating young girls prior to sexual debut, the target of most current vaccination programs. Protection offered by Cervarix against nonvaccine types (mainly 31, 33, and 45) might potentially allow for 11%-16% additional protection against cervical cancers, compared to a vaccine only offering protection against HPV-16/18. Another recent study directly compared the antibody response of Cervarix to that of quadrivalent HPV-6/11/16/18 vaccine (Gardasil; Merck, Whitehouse Station, NJ, USA). Cervarix induced significantly superior neutralizing antibody levels as compared with Gardasil for HPV-16 and HPV-18 in all age groups studied. This may translate into more women having detectable (neutralizing) antibodies in cervicovaginal secretions for HPV-16 and HPV-18 after vaccination with Cervarix when compared with Gardasil. Cervarix induced significantly higher frequencies of antigen-specific memory B-cells and T-cells in responders for HPV-16 and HPV-18 as compared with Gardasil. Cervarix continues to show sustained high levels of total and neutralizing antibodies for HPV-16 and HPV-18, 7.3 years after vaccination. This is associated with high efficacy and no breakthrough cases in the HPV-naïve population, and is the longest duration follow-up for safety, immunogenicity, and efficacy for any licensed HPV vaccine to date. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
26. Human parvovirus B19: ELISA and immunoblot assays
- Author
-
Schwarz Tf, Friedrich Deinhardt, and Michael Roggendorf
- Subjects
viruses ,Enzyme-Linked Immunosorbent Assay ,Biology ,Antibodies, Viral ,Rubella ,Parvoviridae ,Virus ,Parvoviridae Infections ,Antigen ,hemic and lymphatic diseases ,Virology ,medicine ,Humans ,Rheumatoid factor ,Immunoassay ,Parvovirus ,Nucleic Acid Hybridization ,virus diseases ,Outbreak ,medicine.disease ,biology.organism_classification ,Immunoglobulin M ,Immunoglobulin G ,DNA, Viral ,Immunology ,biology.protein ,Antibody - Abstract
An ELISA for the detection of specific IgM and IgG against human parvovirus B19 (anti-B19 IgM and IgG) and B19 antigen is described. With ELISA anti-B19 IgM could be detected for up to 20 weeks after viraemia. Four to five months after B19 infection anti-B19 IgG titres range between 10−6 and 10−7. Nonspecific reactions with rheumatoid factor or IgM against rubella were not found. The ELISA for B19 antigen was shown to be as sensitive as DNA hybridisation. With immunoblotting two viral proteins of 83 kd (VP1) and 58 kd (VP2) were demonstrated. After acute infection antibodies to VP2 appear before antibodies to VP1. Immunoblotting might be used in pregnancy to determine the time of maternal infection. In a survey of a B19 outbreak in a school for medical technology, 6 (28.6%) of 21 non-immune females seroconverted.
- Published
- 1988
27. Seroprevalence of human parvovirus B19 infection in Sao Tomé and Principe, Malawi and Mascarene Islands
- Author
-
Lutz G. Gürtler, G. Zoulek, Michael Roggendorf, Friedrich Deinhardt, and Schwarz Tf
- Subjects
Adult ,Male ,Veterinary medicine ,Malawi ,Adolescent ,viruses ,Immunology ,Enzyme-Linked Immunosorbent Assay ,Human parvovirus ,Antibodies, Viral ,Parvoviridae ,Parvoviridae Infections ,Random Allocation ,Indian Ocean Islands ,hemic and lymphatic diseases ,parasitic diseases ,Seroprevalence ,Humans ,Child ,Aged ,Random allocation ,Aged, 80 and over ,biology ,Parvovirus ,Capture antibody ,virus diseases ,Infant ,Elisa assay ,Middle Aged ,biology.organism_classification ,Virology ,Cross-Sectional Studies ,Child, Preschool ,Immunoglobulin G ,Mauritius ,Mainland ,Female ,human activities - Abstract
The prevalence of antibodies to human parvovirus B19 (anti-B19 IgG) in sera (n = 577) from Sao Tome and Principe, Malawi and Mascarene Islands (Mauritius and Rodriguez Islands) was determined by antibody capture ELISA. The B19 prevalence was 51.5% on Sao Tome and Principe, 58.4% in Malawi, and 55.0% on the Mauritius mainland and 2.2% on Rodriguez Island, indicating that B19 virus is highly prevalent not only in Europe, Japan and the Americas but also in the African region. Rodriguez Islands has a very low B19 prevalence.
- Published
- 1989
28. Immunoglobulins in the prophylaxis of parvovirus B19 infection
- Author
-
Schwarz Tf, Susanne Modrow, Barbara Hottenträger, Jaap M. Middeldorp, Friedrich Deinhardt, Michael Roggendorf, Pathology, CCA - Cancer immunology, CCA - Target Discovery & Preclinial Therapy Development, CCA - Biomarkers, CCA - Evaluation of Cancer Care, AII - Infectious diseases, and AII - Cancer immunology
- Subjects
Parvoviridae ,Pregnancy ,biology ,Parvovirus ,business.industry ,Parvoviridae Infections ,Immunization, Passive ,biology.organism_classification ,medicine.disease ,Antibodies, Viral ,Virology ,Immunoglobulin G ,Infectious Diseases ,biology.protein ,medicine ,Immunology and Allergy ,Humans ,Female ,Antibody ,Pregnancy Complications, Infectious ,business
29. New oligopeptide immunoglobulin G test for human parvovirus B19 antibodies
- Author
-
R. Sumazakl, W. Scharti, Hans Wolf, Susanne Modrow, Schwarz Tf, Gundula Jäger, Barbara Hottenträger, Jaap M. Middeldorp, Michael Roggendorf, Brigitte Höflacher, Pathology, CCA - Cancer immunology, CCA - Target Discovery & Preclinial Therapy Development, CCA - Biomarkers, CCA - Evaluation of Cancer Care, AII - Infectious diseases, and AII - Cancer immunology
- Subjects
Microbiology (medical) ,viruses ,610 Medizin ,Enzyme-Linked Immunosorbent Assay ,Immunoglobulin E ,Antibodies, Viral ,Sensitivity and Specificity ,Immunoglobulin G ,Parvoviridae ,Parvoviridae Infections ,Immunoglobulin G/analysis ,Antibodies, Viral/blood ,Antigen ,hemic and lymphatic diseases ,medicine ,Humans ,Antigens, Viral ,ddc:610 ,biology ,medicine.diagnostic_test ,Parvoviridae/immunology ,Parvovirus ,virus diseases ,Parvoviridae Infections/diagnosis ,biology.organism_classification ,Virology ,Molecular biology ,Titer ,Immunoassay ,biology.protein ,Antibody ,Oligopeptides ,Oligopeptides/immunology ,Research Article - Abstract
A new, highly sensitive and specific enzyme immunoassay using oligopeptides as antigen (enzyme-linked immunosorbent assay [ELISA] B19-OP) for detecting parvovirus B19-specific immunoglobulin G (IgG) was established. As antigens, B19-specific oligopeptides of 24 and 30 kDa derived from a 196-kDa fusion protein of beta-galactosidase and viral capsid protein (VPI) of B19 after CNBr cleavage and separation by high-pressure liquid chromatography were used. Of 139 serum specimens tested in parallel for anti-B19 IgG by standard ELISA using B19 particles as antigen and by ELISA B19-OP, 73 (52.5%) were positive and 63 (45.3%) were negative in both tests, and 3 (2.2%) were negative by standard ELISA but positive by ELISA B19-OP and by immunoblot. By using ELISA B19-OP, it was possible to detect anti-B19 IgG in an asymptomatic blood donor 4 weeks after acute infection, and anti-B19 IgG titers of 10(-5) could be measured in convalescent-phase sera.
30. Human parvovirus B19 infection and juvenile chronic polyarthritis
- Author
-
Friedrich Deinhardt, Schwarz Tf, Michael Roggendorf, and H. Suschke
- Subjects
Microbiology (medical) ,Infectious Diseases ,business.industry ,Immunology ,Juvenile Chronic Polyarthritis ,Medicine ,Polyarthritis ,General Medicine ,Human parvovirus ,business ,medicine.disease ,Virology - Published
- 1987
31. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.
- Author
-
Wheeler CM, Castellsagué X, Garland SM, Szarewski A, Paavonen J, Naud P, Salmerón J, Chow SN, Apter D, Kitchener H, Teixeira JC, Skinner SR, Jaisamrarn U, Limson G, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, and Harper DM
- Abstract
BACKGROUND: We evaluated the efficacy of the human papillomavirus HPV-16/18 AS04-adjuvanted vaccine against non-vaccine oncogenic HPV types in the end-of-study analysis after 4 years of follow-up in PATRICIA (PApilloma TRIal against Cancer In young Adults). METHODS: Healthy women aged 15-25 years with no more than six lifetime sexual partners were included in PATRICIA irrespective of their baseline HPV DNA status, HPV-16 or HPV-18 serostatus, or cytology. Women were randomly assigned (1:1) to HPV-16/18 vaccine or a control hepatitis A vaccine, via an internet-based central randomisation system using a minimisation algorithm to account for age ranges and study sites. The study was double-blind. The primary endpoint of PATRICIA has been reported previously; the present analysis evaluates cross-protective vaccine efficacy against non-vaccine oncogenic HPV types in the end-of-study analysis. Analyses were done for three cohorts: the according-to-protocol cohort for efficacy (ATP-E; vaccine n=8067, control n=8047), total vaccinated HPV-naive cohort (TVC-naive; no evidence of infection with 14 oncogenic HPV types at baseline, approximating young adolescents before sexual debut; vaccine n=5824, control n=5820), and the total vaccinated cohort (TVC; all women who received at least one vaccine dose, approximating catch-up populations that include sexually active women; vaccine n=9319, control=9325). Vaccine efficacy was evaluated against 6-month persistent infection, cervical intraepithelial neoplasia grade 2 or greater (CIN2+) associated with 12 non-vaccine HPV types (individually or as composite endpoints), and CIN3+ associated with the composite of 12 non-vaccine HPV types. This study is registered with ClinicalTrials.gov, number NCT00122681. FINDINGS: Consistent vaccine efficacy against persistent infection and CIN2+ (with or without HPV-16/18 co-infection) was seen across cohorts for HPV-33, HPV-31, HPV-45, and HPV-51. In the most conservative analysis of vaccine efficacy against CIN2+, where all cases co-infected with HPV-16/18 were removed, vaccine efficacy was noted for HPV-33 in all cohorts, and for HPV-31 in the ATP-E and TVC-naive. Vaccine efficacy against CIN2+ associated with the composite of 12 non-vaccine HPV types (31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68), with or without HPV-16/18 co-infection, was 46·8% (95% CI 30·7-59·4) in the ATP-E, 56·2% (37·2-69·9) in the TVC-naive, and 34·2% (20·4-45·8) in the TVC. Corresponding values for CIN3+ were 73·8% (48·3-87·9), 91·4% (65·0-99·0), and 47·5% (22·8-64·8). INTERPRETATION: Data from the end-of-study analysis of PATRICIA show cross-protective efficacy of the HPV-16/18 vaccine against four oncogenic non-vaccine HPV types-HPV-33, HPV-31, HPV-45, and HPV-51-in different trial cohorts representing diverse groups of women. FUNDING: GlaxoSmithKline Biologicals. [ABSTRACT FROM AUTHOR]
- Published
- 2012
32. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.
- Author
-
Lehtinen M, Paavonen J, Wheeler CM, Jaisamrarn U, Garland SM, Castellsagué X, Skinner SR, Apter D, Naud P, Salmerón J, Chow SN, Kitchener H, Teixeira JC, Hedrick J, Limson G, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, and Poppe WA
- Abstract
BACKGROUND: Cervical intraepithelial neoplasia grade 2 or greater (CIN2+) is the surrogate endpoint used in licensure trials of human papillomavirus (HPV) vaccines. Vaccine efficacy against CIN3+, the immediate precursor to invasive cervical cancer, is more difficult to measure because of its lower incidence, but provides the most stringent evidence of potential cancer prevention. We report vaccine efficacy against CIN3+ and adenocarcinoma in situ (AIS) in the end-of-study analysis of PATRICIA (PApilloma TRIal against Cancer In young Adults). METHODS: Healthy women aged 15-25 years with no more than six lifetime sexual partners were included in PATRICIA, irrespective of their baseline HPV DNA status, HPV-16 or HPV-18 serostatus, or cytology. Women were randomly assigned (1:1) to receive an HPV-16/18 AS04-adjuvanted vaccine or a control hepatitis A vaccine via an internet-based central randomisation system using a minimisation algorithm to account for age ranges and study sites. The patients and study investigators were masked to allocated vaccine. The primary endpoint of PATRICIA has been reported previously. In the present end-of-study analysis, we focus on CIN3+ and AIS in the populations of most clinical interest, the total vaccinated cohort (TVC) and the TVC-naive. The TVC comprised all women who received at least one vaccine dose, approximating catch-up populations and including sexually active women (vaccine n=9319; control=9325). The TVC-naive comprised women with no evidence of oncogenic HPV infection at baseline, approximating early adolescent HPV exposure (vaccine n=5824; control=5820). This study is registered with ClinicalTrials.gov, number NCT00122681. FINDINGS: Vaccine efficacy against CIN3+ associated with HPV-16/18 was 100% (95% CI 85·5-100) in the TVC-naive and 45·7% (22·9-62·2) in the TVC. Vaccine efficacy against all CIN3+ (irrespective of HPV type in the lesion and including lesions with no HPV DNA detected) was 93·2% (78·9-98·7) in the TVC-naive and 45·6% (28·8-58·7) in the TVC. In the TVC-naive, vaccine efficacy against all CIN3+ was higher than 90% in all age groups. In the TVC, vaccine efficacy against all CIN3+ and CIN3+ associated with HPV-16/18 was highest in the 15-17 year age group and progressively decreased in the 18-20 year and 21-25 year age groups. Vaccine efficacy against all AIS was 100% (31·0-100) and 76·9% (16·0-95·8) in the TVC-naive and TVC, respectively. Serious adverse events occurred in 835 (9·0%) and 829 (8·9%) women in the vaccine and control groups, respectively; only ten events (0·1%) and five events (0·1%), respectively, were considered to be related to vaccination. INTERPRETATION: PATRICIA end-of-study results show excellent vaccine efficacy against CIN3+ and AIS irrespective of HPV DNA in the lesion. Population-based vaccination that incorporates the HPV-16/18 vaccine and high coverage of early adolescents might have the potential to substantially reduce the incidence of cervical cancer. FUNDING: GlaxoSmithKline Biologicals. [ABSTRACT FROM AUTHOR]
- Published
- 2012
33. Noninferior Immunogenicity and Consistent Safety of Respiratory Syncytial Virus Prefusion F Protein Vaccine in Adults 50-59 Years Compared to ≥60 Years of Age.
- Author
-
Ferguson M, Schwarz TF, Núñez SA, Rodríguez-García J, Mital M, Zala C, Schmitt B, Toursarkissian N, Mazarro DO, Großkopf J, Voors-Pette C, Mehta H, Hailemariam HA, de Heusch M, Salaun B, Damaso S, David MP, Descamps D, Hill J, Vandermeulen C, and Hulstrøm V
- Abstract
Background: The adjuvanted respiratory syncytial virus (RSV) prefusion F protein-based vaccine (RSVPreF3 OA) is approved in adults aged ≥60 years. We evaluated RSVPreF3 OA immunogenicity and safety in adults aged 50-59 years without or with increased risk for RSV disease due to specific chronic medical conditions., Methods: This observer-blind, phase 3, noninferiority trial included adults aged 50-59 years, stratified into 2 subcohorts: those with and those without predefined, stable, chronic medical conditions leading to an increased risk for RSV disease. Participants in both subcohorts were randomized 2:1 to receive RSVPreF3 OA or placebo. A control group of adults aged ≥60 years received RSVPreF3 OA. Primary outcomes were RSV-A and RSV-B neutralization titers (geometric mean titer ratios and sero-response rate differences) 1 month post-vaccination in 50-59-year-olds versus ≥60-year-olds. Cell-mediated immunity and safety were also assessed., Results: The exposed population included 1152 participants aged 50-59 years and 381 participants aged ≥60 years. RSVPreF3 OA was immunologically noninferior in 50-59-year-olds versus ≥60-year-olds; noninferiority criteria were met for RSV-A and RSV-B neutralization titers in those with and those without increased risk for RSV disease. Frequencies of RSVPreF3-specific polyfunctional CD4+ T cells increased substantially from pre- to 1 month post-vaccination. Most solicited adverse events had mild-to-moderate intensity and were transient. Unsolicited and serious adverse event rates were similar in all groups., Conclusions: RSVPreF3 OA was immunologically noninferior in 50-59-year-olds compared to ≥60-year-olds, in whom efficacy was previously demonstrated. The safety profile in 50-59-year-olds was consistent with that in ≥60-year-olds., Clinical Trial Registration: ClinicalTrials.gov: NCT05590403., Competing Interests: Potential conflicts of interest . H. A. H., M. d. H., B. S., S. D., M.-P. D., D. D., J. H., C. V., and V. H. are/were GSK employees at the time when the study was designed and/or conducted. H. A. H., M. d. H., B. S., S. D., M.-P. D., D. D., J. H., and V. H. hold shares in GSK as part of their employee remuneration. M.-P. D. is a co-applicant on a pending patent filed by GSK. M. F. received study-related payments for training and study conduct from GSK. T. F. S. received honoraria for lectures from AstraZeneca, Bavarian Nordic, Biogen, CSL-Seqirus, GSK, Janssen-Cilag, Merck-Serono, Moderna, Novavax, MSD, Pfizer, Roche, Sanofi-Aventis, and Takeda; he participated on advisory boards for Bavarian Nordic, CSL-Seqirus, BioNTech, GSK, Moderna, Novavax, and Takeda. S. A. N. declares study-related payments to his institution from GSK and support from GSK to attend investigators meetings. J. R.-G. declares study-related payments from GSK and honoraria and support for attending meetings and/or travel from GSK, Pfizer, and Sanofi-MSD; he also participated on data and safety monitoring boards or advisory boards from GSK and Pfizer. C. Z. received grants from GSK for the conduct of this study and support from GSK for attending meetings. J. G. declares study-related payments from GSK; grants from Novartis, Pharmalog, New Amsterdam Pharma, Syneos, Winecker Pharma, and Lilly; and consulting fees, honoraria, payment for expert testimony, and support for attending meetings and/or travel from GSK. C. V.-P. is a former employee of QPS Netherlands B.V. The other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed., (© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America.)
- Published
- 2024
- Full Text
- View/download PDF
34. Immunogenicity and Safety Following 1 Dose of AS01E-Adjuvanted Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults: A Phase 3 Trial.
- Author
-
Schwarz TF, Hwang SJ, Ylisastigui P, Liu CS, Takazawa K, Yono M, Ervin JE, Andrews CP, Fogarty C, Eckermann T, Collete D, de Heusch M, De Schrevel N, Salaun B, Lambert A, Maréchal C, Olivier A, Nakanwagi P, Lievens M, and Hulstrøm V
- Subjects
- Humans, Male, Female, Aged, Middle Aged, Viral Fusion Proteins immunology, Viral Fusion Proteins administration & dosage, Antibodies, Neutralizing blood, Immunogenicity, Vaccine, Aged, 80 and over, Adjuvants, Vaccine administration & dosage, Respiratory Syncytial Virus Vaccines immunology, Respiratory Syncytial Virus Vaccines administration & dosage, Respiratory Syncytial Virus Vaccines adverse effects, Respiratory Syncytial Virus Infections prevention & control, Respiratory Syncytial Virus Infections immunology, Antibodies, Viral blood, Respiratory Syncytial Virus, Human immunology
- Abstract
Background: The recently approved AS01E-adjuvanted respiratory syncytial virus (RSV) prefusion F protein-based vaccine for older adults (RSVPreF3 OA) demonstrated high efficacy against RSV-related disease in ≥60-year-olds., Methods: This ongoing phase 3 study in ≥60-year-olds evaluates immune persistence until 3 years after RSVPreF3 OA vaccination. Here, we describe interim results on humoral and cell-mediated immunogenicity, reactogenicity, and safety until 1 year post-dose 1., Results: In total, 1653 participants were vaccinated. One month post-dose 1, neutralization titers increased 10.5-fold (RSV-A) and 7.8-fold (RSV-B) vs pre-dose 1. Titers then declined to levels 4.4-fold (RSV-A) and 3.5-fold (RSV-B) above pre-dose 1 at month 6 and remained 3.1-fold (RSV-A) and 2.3-fold (RSV-B) above pre-dose 1 levels after 1 year. RSVPreF3-binding immunoglobulin G levels and CD4+ T-cell frequencies showed similar kinetics. Solicited administration-site and systemic adverse events (mostly mild to moderate and transient) were reported by 62.2% and 49.5% of participants. Serious adverse events were reported by 3.9% of participants within 6 months post-dose 1; 1 case was considered vaccine related., Conclusions: One RSVPreF3 OA dose elicited cell-mediated and RSV-A- and RSV-B-specific humoral immune responses that declined over time but remained above pre-dose 1 levels for at least 1 year. The vaccine was well tolerated with an acceptable safety profile. Clinical Trials Registration. NCT04732871 (ClinicalTrials.gov)., Competing Interests: Potential conflicts of interest. T. F. S. reports having received payment or honoraria for lecturing or advisory boards from GSK, AstraZeneca, Bavarian Nordic, Biogen, BioNTech, Janssen-Cilag, Merck-Serono, Moderna, MSD, Pfizer, Roche, Sanofi-Aventis, Seqirus, Takeda, and for conducting clinical vaccine trials from GSK, Pfizer, and Serum Institute of India. S.-J. H. received research support and consultation fees from GSK. P. Y. assisted as Site Principal Investigator for the current study. C. P. A. was a paid Site Principal Investigator for the study and has received consulting fees from Merck and Boehringer Ingelheim. D. C., M. d. H., N. D. S., B. S., A. L., C. M., A. O., P. N., M. L., and V. H. were employees of GSK at the time the study was designed, initiated, and/or conducted. D. C., M. d. H., N. D. S., B. S., C.M., A. O., M. L., and V. H. hold shares of stock in the company as part of their employee remuneration. A. O. is a co-applicant on a pending patent filed by GSK. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed., (© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America.)
- Published
- 2024
- Full Text
- View/download PDF
35. Efficacy and Safety of Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in Older Adults Over 2 RSV Seasons.
- Author
-
Ison MG, Papi A, Athan E, Feldman RG, Langley JM, Lee DG, Leroux-Roels I, Martinon-Torres F, Schwarz TF, van Zyl-Smit RN, Verheust C, Dezutter N, Gruselle O, Fissette L, David MP, Kostanyan L, Hulstrøm V, Olivier A, Van der Wielen M, and Descamps D
- Subjects
- Humans, Male, Female, Aged, Middle Aged, Antibodies, Viral blood, Aged, 80 and over, Seasons, Vaccine Efficacy, Double-Blind Method, Immunization, Secondary, Respiratory Syncytial Virus Infections prevention & control, Respiratory Syncytial Virus Vaccines immunology, Respiratory Syncytial Virus Vaccines administration & dosage, Respiratory Syncytial Virus Vaccines adverse effects, Respiratory Syncytial Virus, Human immunology, Viral Fusion Proteins immunology
- Abstract
Background: The adjuvanted RSV prefusion F protein-based vaccine (RSVPreF3 OA) was efficacious against RSV-related lower respiratory tract disease (RSV-LRTD) in ≥60-years-olds over 1 RSV season. We evaluated efficacy and safety of 1 RSVPreF3 OA dose and of 2 RSVPreF3 OA doses given 1 year apart against RSV-LRTD over 2 RSV seasons post-dose 1., Methods: In this phase 3, blinded trial, ≥60-year-olds were randomized (1:1) to receive RSVPreF3 OA or placebo pre-season 1. RSVPreF3 OA recipients were re-randomized (1:1) to receive a second RSVPreF3 OA dose (RSV_revaccination group) or placebo (RSV_1dose group) pre-season 2; participants who received placebo pre-season 1 received placebo pre-season 2 (placebo group). Efficacy of both vaccine regimens against RSV-LRTD was evaluated over 2 seasons combined (confirmatory secondary objective, success criterion: lower limits of 2-sided CIs around efficacy estimates >20%)., Results: The efficacy analysis comprised 24 967 participants (RSV_1dose: 6227; RSV_revaccination: 6242; placebo: 12 498). Median efficacy follow-up was 17.8 months. Efficacy over 2 seasons of 1 RSVPreF3 OA dose was 67.2% (97.5% CI: 48.2-80.0%) against RSV-LRTD and 78.8% (95% CI: 52.6-92.0%) against severe RSV-LRTD. Efficacy over 2 seasons of a first dose followed by revaccination was 67.1% (97.5% CI: 48.1-80.0%) against RSV-LRTD and 78.8% (95% CI: 52.5-92.0%) against severe RSV-LRTD. Reactogenicity/safety of the revaccination dose were similar to dose 1., Conclusions: One RSVPreF3 OA dose was efficacious against RSV-LRTD over 2 RSV seasons in ≥60-year-olds. Revaccination 1 year post-dose 1 was well tolerated but did not seem to provide additional efficacy benefit in the overall study population., Clinical Trials Registration: ClinicalTrials.gov: NCT04886596., Competing Interests: Potential conflicts of interest . M. G. I. declares that research support from GSK was paid to his previous institution, Northwestern University; he received consulting fees from Adagio Therapeutics, ADMA Biologics, Adamis Pharmaceuticals, AlloVir, Atea, Cidara Therapeutics, Genentech/Roche, Janssen, Shionogi, Takeda, Talaris, and Eurofins Viracor; and payment for participating in data safety monitoring boards or advisory boards from Adamis Pharmaceuticals, AlloVir, National Institutes of Health, CSL Behring, Janssen, Merck, Seqirus, Takeda, and Talaris; all of these ended in December 2022; M. G. I. also receives author royalties from UpToDate, which is ongoing, and serves as Chair of the International Society for Influenza and other Respiratory Virus Diseases Antiviral Group and was Editor-in-Chief of Transplant Infectious Disease. A. P. declares funding from GSK for conducting the trial. A. P. also declares that his institution received grants from Chiesi, AstraZeneca, GSK, Sanofi, and Agenzia Italiana del Farmaco; that he received consulting fees from Chiesi, AstraZeneca, GSK, Novartis, Sanofi, Avillion, and ELPEN Pharmaceuticals; payment for participation in advisory boards from Chiesi, AstraZeneca, GSK, Novartis, Sanofi, IQVIA, Avillion, and ELPEN Pharmaceuticals; and honoraria from Chiesi, AstraZeneca, GSK, Menarini, Novartis, Zambon, Mundipharma, Sanofi, Edmond Pharmaceuticals, IQVIA, Avillion, and ELPEN Pharmaceuticals. R. G. F. declares having received payment from GSK for lectures and support for travel related to these activities. J. M. L. reports grants from GSK paid to her institution for the conduct of the trial and from GSK, Pfizer, Merck, Moderna, Sanofi, Inventprise, and VBI Vaccines for other trials; J. M. L. also reports being a board member of Seqirus and participating on a data safety monitoring board or advisory board for Vaxcyte; she is an expert panelist for Canada's Drug and Health Technology Agency for the review of nirsevimab. I. L.-R. declares that her institution received funding from GSK for conducting this trial; from Icosavax, Virometix, Janssen Vaccines, Curevac, Moderna, Osivax, MSD, ICON Genetics, and OSE Immunotherapeutics for other vaccine trials; from Janssen Vaccines and MSD for consulting services; and from Janssen Vaccines for participation on a data safety monitoring board or advisory board. F. M.-T. declares that his institution received payment from GSK for conducting this trial and from Ablynx, Abbott, Seqirus, Sanofi, MSD, Merck, Pfizer, Roche, Regeneron, Janssen, Medimmune, Novavax, Novartis, and GSK for other vaccine trials; F. M.-T. also reports receiving honoraria for lectures from Sanofi, MSD, Moderna, GSK, Biofabri, AstraZeneca, Novavax, Janssen, and Pfizer; payment of travel expenses and meeting fees from Pfizer, MSD, GSK, and Sanofi; and participation on data safety monitoring boards or advisory boards for Pfizer and Biofabri; F. M.-T. is also a member of the World Health Organization’s (WHO's) European Technical Advisory Group of Experts, coordinator of the Spanish Pediatric Clinical Trials Network, and coordinator of the WHO Collaborating Center for Vaccine Safety of Santiago de Compostela. T. F. S. reports honoraria and/or participation on data safety monitoring boards or advisory boards from Alexion, AstraZeneca, Bavarian Nordic, Biogen, Biontech, GSK, Janssen-Cilag, Merck-Serono, Moderna, MSD, Novavax, Pfizer, Roche, Sanofi-Aventis, Seqirus, Synlab, Takeda, and va-Q-tec. R. N. v. Z.-S. reports that his institution received support from Boehringer Ingelheim for the Interstitial Lung Diseases (ILD) registry and that he received consulting fees from GSK and honoraria for lectures from Glenmark, Boehringer Ingelheim, Cipla, and Novartis; R. N. v. Z.-S. also participated on data safety monitoring boards or advisory boards for OnQ SA; he is president of the South African Thoracic Society and co-chair of the International Health Committee of the American Thoracic Society. C. V., N. D., O. G., L. F., M.-P. D., L. K., V. H., A. O., M. V. d. W., and D. D. are employed by GSK and have stock options or shares from GSK. N. D. is co-applicant on a pending patent for vaccination against RSV and has stock options from Haleon. L. F., M.-P. D., A. O., and M. V. d. W. are co-applicants on a pending patent filed by GSK. The other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed., (© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America.)
- Published
- 2024
- Full Text
- View/download PDF
36. Cell-based influenza vaccines: An effective vaccine option for under 60-year-olds.
- Author
-
Gärtner BC, Beier D, Gosch G, Wahle K, Wendt L, Förster LC, Schmidt KJ, and Schwarz TF
- Abstract
Aim: Seasonal influenza poses a significant burden of disease, affecting not only older adults but also individuals under the age of 60. It carries a high economic burden, mainly driven by influenza-associated productivity losses in the working population. Conventional egg-based influenza vaccines may have reduced effectiveness due to antigen adaptation in eggs. In contrast, cell-based influenza vaccines are less likely to be affected by such antigen adaptation. This review aims to present real-world data (RWD) comparing the effectiveness of quadrivalent cell-based (QIVc) and egg-based (QIVe) influenza vaccines over three consecutive seasons., Methods: A comprehensive review was conducted, analyzing RWD from retrospective cohort and case-control studies on the relative vaccine effectiveness (rVE) of QIVc versus QIVe during the 2017/18-2019/20 seasons., Results: This study included six retrospective cohort studies and one case-control study, with a combined total of approximately 29 million participants. A cohort study involving people aged ≥4 years during the 2017/18 season showed a statistically significant rVE of QIVc compared to QIVe in preventing influenza-like illness, with a value of 36.2%. QIVc demonstrated statistically significant superiority over QIVe in preventing outpatient and inpatient medical encounters as observed in two cohort studies conducted during the 2018/19 and 2019/20 seasons. The rVE of QIVc compared to QIVe was found to be 7.6% in individuals aged ≥4 years and 9.5% in individuals aged ≥18 years. Three additional cohort studies conducted between 2017/18-2019/20 reported a statistically significant improvement in rVE (5.3-14.4%) of QIVc compared to QIVe in preventing influenza-related hospitalizations and emergency department visits due to influenza in individuals aged 4-64 years. In a case-control study across all three seasons, QIVc showed statistically significantly higher effectiveness compared to QIVe in preventing test-confirmed influenza, with rVEs of 10.0-14.8%., Conclusions: RWD from the 2017/18-2019/20 seasons demonstrated that QIVc is more effective than QIVe in preventing influenza-related outcomes in individuals aged 4-64 years. Preferential use of cell-based influenza vaccines, as opposed to conventional egg-based vaccines, could reduce the burden of influenza-related symptoms on individuals and alleviate the economic impact on the German population under 60 years of age., Competing Interests: CSL Seqirus GmbH funded the publication.Dr. Dietmar Beier: Advisory Board for CSL Seqirus.Prof. Dr. Barbara C. Gärtner: Advisory Board and honoraria for lectures for CSL Seqirus, Sanofi, GSK, Moderna, BioNTech, Pfizer, Viatris.Dr. Gunther Gosch: Lecturing activities and participation in advisory boards for AstraZeneca, CLS Seqirus, GSK, MSD, Pfizer, Sanofi Aventis. Prof. Dr. Klaus Wahle: Lectures and participation in advisory boards on behalf of or for SPMSD, CSL Seqirus, Pfizer, GSK, BioNTech. Dr. Luise Wendt: -Dr. Laura-Christin Förster is employed by CSL Seqirus GmbH.Kim J. Schmidt is employed by Xcenda GmbH, which received funding from CSL Seqirus GmbH for the preparation of this manuscript.Prof. Dr. Tino F. Schwarz: Honoraria for consulting and lectures for Alexion, AstraZeneca, Bavarian Nordic, Biogen, BioNTech, GSK, Janssen-Cilag, Merck-Serono, Moderna, MSD, Novavax, Pfizer, Roche, Sanofi-Aventis, CSL Seqirus, Synlab, Takeda and va-Q-tec., (Copyright © 2024 Gärtner et al.)
- Published
- 2024
- Full Text
- View/download PDF
37. Safety, Tolerability, and Immunogenicity of aH5N1 Vaccine in Adults with and without Underlying Medical Conditions.
- Author
-
Jelinek T, Schwarz TF, Reisinger E, Malfertheiner P, Versage E, Van Twuijver E, and Hohenboken M
- Abstract
Influenza pandemics pose a serious risk to the global population, with the potential for high morbidity and mortality. An adjuvanted H5N1 vaccine (aH5N1) has been approved for prophylaxis against the avian influenza virus H5N1, which is a likely cause of future pandemics. In this phase-III, stratified, randomized, controlled, observer-blind, multicenter study, we evaluated the safety and immunogenicity of aH5N1 in four separate groups of adults: adults 18-60 years of age who were healthy or had high-risk medical conditions and older adults ≥61 years of age who were healthy or had high-risk medical conditions. Subjects were randomly assigned to aH5N1 or the comparator, adjuvanted trivalent seasonal influenza vaccine (aTIV). Antibody responses to aH5N1 were increased in all four subgroups and, within each age stratum, largely consistent between healthy subjects and those with medical conditions. Injection-site pain was reported by 66-73% of younger and 36-42% of older-aH5N1 recipients, and fatigue and myalgia were reported by 22-41% of subjects across age and health subgroups. No serious adverse events or deaths were considered related to the study vaccine. In conclusion, aH5N1 increased antibody responses regardless of age or health status and demonstrated a clinically acceptable safety and tolerability profile.
- Published
- 2024
- Full Text
- View/download PDF
38. Reply to letter to editor by Yin et al.
- Author
-
Gärtner BC, Kwetkat A, Beier D, Wahle K, Schmidt KJ, and Schwarz TF
- Abstract
Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: [GBC received honoraria from Seqirus, Viatris, Sanofi, GSK, Biontech, and Moderna. KA provided research support to the Robert Bosch Foundation – Research College Geriatrics, and Pfizer Pharma GmbH; provided consulting/expert support to Seqirus, GlaxoSmithKline GmbH & Co. KG, Pfizer Pharma GmbH, Sanofi-Pasteur, AstraZeneca; lecturing for Pfizer Pharma GmbH, Fa. MSD, Fa. Novartis, Fa. Daiichi-Sankyo, Fa. Bristol-Myers Squibb, Fa. Sanofi-Pasteur; holds honorary positions as speaker of the vaccination working group of the German Geriatrics Society e.V. (DGG e.V.) and member of the DRG project group of the Federal Geriatrics Association e.V. (BVG e.V.). BD participated in an advisory board for Seqirus. WK provided lecture activities to and participated in advisory boards for SPMSD, Seqirus, Pfizer, GSK, Biontech. SKJ is employed by Xcenda GmbH which received funding from Seqirus GmbH. STF provided lecture activities and consulting support to Biogen, Merck-Serono, GlaxoSmithKline, Sanofi-Aventis, Pfizer, Seqirus, Synlab, AstraZeneca, Roche, MSD, va-Q-tec, Bavarian Nordic, Janssen-Cilag, Alexion, Takeda, Biontech, MSD, Moderna.].
- Published
- 2024
- Full Text
- View/download PDF
39. The respiratory syncytial virus prefusion F protein vaccine attenuates the severity of respiratory syncytial virus-associated disease in breakthrough infections in adults ≥60 years of age.
- Author
-
Curran D, Matthews S, Cabrera ES, Pérez SN, Breva LP, Rämet M, Helman L, Park DW, Schwarz TF, Melendez IMG, Schaefer A, Roy N, Stephan B, Molnar D, Kostanyan L, Powers JH 3rd, and Hulstrøm V
- Subjects
- Humans, Aged, Middle Aged, Breakthrough Infections, Viral Fusion Proteins, Antibodies, Viral, Antibodies, Neutralizing, Respiratory Syncytial Virus Vaccines therapeutic use, Respiratory Syncytial Virus Infections epidemiology, Respiratory Syncytial Virus Infections prevention & control, Respiratory Syncytial Virus, Human, Respiratory Tract Infections, Influenza, Human prevention & control, Influenza, Human drug therapy
- Abstract
Background: Respiratory syncytial virus (RSV) is a contagious pathogen causing acute respiratory infections (ARIs). Symptoms range from mild upper respiratory tract infections to potentially life-threatening lower respiratory tract disease (LRTD). In adults ≥60 years old, vaccine efficacy of a candidate vaccine for older adults (RSVPreF3 OA) was 71.7% against RSV-ARI and 82.6% against RSV-LRTD (AReSVi-006/NCT04886596). We present the patient-reported outcomes (PROs) from the same trial at the end of the first RSV season in the northern hemisphere (April 2022)., Methods: In this phase 3 trial, adults aged ≥60 years were randomized (1:1) to receive one dose of RSVPreF3 OA vaccine or placebo. PROs were assessed using InFLUenza Patient-Reported Outcome (FLU-PRO), Short Form-12 (SF-12), and EuroQol-5 Dimension (EQ-5D) questionnaires. Peak FLU-PRO Chest/Respiratory scores during the first 7 days from ARI episode onset were compared using a Wilcoxon test. Least squares mean (LSMean) of SF-12 physical functioning (PF) and EQ-5D health utility scores were estimated using mixed effects models., Results: In the RSVPreF3 OA group ( N = 12,466), 27 first RSV-ARI episodes were observed versus 95 in the Placebo group ( N = 12,494). Median peak FLU-PRO Chest/Respiratory scores were lower in RSVPreF3 OA (1.07) versus Placebo group (1.86); p = 0.0258. LSMean group differences for the PF and EQ-5D health utility score were 7.00 (95% confidence interval [CI]: -9.86, 23.85; p = 0.4125) and 0.0786 (95% CI: -0.0340, 0.1913; p = 0.1695)., Conclusions: The RSVPreF3 OA vaccine, in addition to preventing infection, attenuated the severity of RSV-associated symptoms in breakthrough infections, with trends of reduced impact on PF and health utility., Competing Interests: During this study, Eliazar Sabater Cabrera, Desmond Curran, Veronica Hulstrøm, Lusine Kostanyan, and Daniel Molnar were GSK employees. Eliazar Sabater Cabrera, Desmond Curran, Veronica Hulstrøm, Lusine Kostanyan, and Daniel Molnar hold shares in GSK. Isabel Maria Galan Melendez was an investigator for the study of RSV OA‐006 and declares to have received payments from GSK per contract, as well as equipment on loan and study materials. Silvia Narejos Pérez participated as principal investigator (PI) in clinical trials with different sponsors, including GSK and received financial support during the present manuscript. As a PI, she collaborated in the presentation of the results of clinical trials of vaccines and received financial support for attending meetings and/or travel. Laura Helman received payment for completing the study work and was given financial support for attending meetings and/or travel as an investigator. During the development of the study, John H. Powers III was a consultant for GSK and Vir on the clinical study design. Besides that, he received consulting fees from Adaptive Phage, Arrevus, Atheln, Bavarian Nordic, Cellularity, Eicos, Evofem, Eyecheck, Gilead, Mustang, OPKO, Otsuka, Resolve, Romark, Spine BioPharma, and UTIlity. He is an unpaid board member of Health Literacy Media. Mika Rämet declares that his institute was sponsored by GSK to perform the current study. Tino Schwarz has received honoraria for lecturing or advisory boards from Alexion, AstraZeneca, Bavarian Nordic, Biogen, Biontech, CSL Seqirus, GSK, Janssen‐Cilag, Merck‐Serono, Moderna, MSD, Novavax, Pfizer, Roche, Sanofi‐Aventis, and Takeda and for conducting clinical vaccine trials from GSK, Pfizer, Clover Biopharmaceuticals, and Serum Institute of India. Brigitte Stephan participated as investigator in clinical trials with different sponsors, including GSK. Sean Matthews, Lina Pérez Breva, Nathalie Roy, Dae Won Park, and Axel Schaefer have nothing to declare., (© 2024 GSK. Influenza and Other Respiratory Viruses published by John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
40. [Enhanced targeted influenza vaccines - New evidence shows higher effectiveness in older adults].
- Author
-
Frühwein M, Schelling J, Wahle K, Beier D, Kwetkat A, and Schwarz TF
- Subjects
- Humans, Middle Aged, Aged, Vaccination, Seasons, Influenza Vaccines, Influenza, Human epidemiology, Immunosenescence
- Abstract
Seasonal influenza causes a significant burden of disease in the German population and is associated with high societal costs. Persons aged 60 years and older are particularly at risk due to immunosenescence and chronic disease and account for a large proportion of influenza-associated hospitalizations and deaths. Adjuvanted, high-dose, recombinant and cell-based influenza vaccines have been developed to improve the effectiveness compared with conventional vaccines. Recent observational studies show better effectiveness of adjuvanted vaccine over conventional vaccines and similar effectiveness to the high-dose vaccine in older adults. Some countries have already considered the new evidence in their vaccination recommendations for the current or earlier seasons. The availability of the vaccines for older adults should also be ensured in Germany to guarantee a high level of vaccination protection., Competing Interests: Die Durchführung der Publikation wurde finanziell von der Seqirus GmbH unterstützt. Dr. Markus Frühwein: – Vorträge/Beratung: Astra Zeneca, Bavarian, Nordic, Biontech, Janßen, GSK, Moderna, MSD, Pfizer, Sanofi, Seqirus, Takeda, Viatris. Prof. Dr. Jörg Schelling: – Beratungshonorare von AstraZeneca, Bavarian Nordic, der GSK Unternehmensgruppe, Sanofi Pasteur, Pfizer, Johnson & Johnson, MSD, BioNTech, Seqirus, Takeda, Viatris – Zahlungen oder Honorare für Vorlesungen, Präsentationen, Rednerbüros, Manuskripterstellung oder Bildungsveranstaltungen von GSK, Sanofi Pasteur, Pfizer, Johnson & Johnson, MSD, BioNTech, Seqirus, Takeda, Viatris – Unterstützung für die Teilnahme an Sitzungen und/oder Reisen von Sanofi Pasteur und Pfizer und Aktienbesitz von Valneva außerhalb der eingereichten Arbeit. Prof. Dr. Klaus Wahle: – Vortragstätigkeiten und Teilnahme an Advisory Boards im Auftrag bzw. für die Firmen SPMSD, Seqirus, Pfizer, GSK, Biontech. Dr. Dietmar Beier: – Advisory Board für Seqirus. Dr. Anja Kwetkat: – Forschungsunterstützung: Robert-Bosch-Stiftung – Forschungskolleg Geriatrie, Pfizer Pharma GmbH – Beratungs-/Gutachtertätigkeit: Projekt Grippeschutz – Seqirus, Advisory Board Prävention Herpes Zoster – GlaxoSmithKline GmbH & Co. KG, Advisory Board Sektorenübergreifendes Impfmanagement – Pfizer Pharma GmbH, Advisory Board Hochdosis Influenza Impfstoff – Sanofi-Pasteur, Advisory Board COVID-19 Impfstoff AZD1222 – AstraZeneca – Vortragstätigkeit: Pfizer Pharma GmbH, Fa. MSD, Fa. Novartis, Fa. Daiichi-Sankyo, Fa. Bristol-Myers Squibb, Fa. Sanofi-Pasteur – Ehrenämter: Sprecherin der AG Impfen der Deutschen Gesellschaft für Geriatrie e. V. (DGG e. V.), Mitglied DRG-Projektgruppe des Bundesverbandes Geriatrie e. V. (BVG e. V.). Prof. Dr. Tino Schwarz: – Honorare für Beratung und Vorträge: Biogen, Merck-Serono, GSK, Sanofi-Aventis, Pfizer, Seqirus, Synlab, AstraZeneca, Roche, MSD, va-Q-tec, Bavarian Nordic, Janssen-Cilag, Alexion, Takeda, Biontech, MSD, Moderna, (The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).)
- Published
- 2023
- Full Text
- View/download PDF
41. Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults.
- Author
-
Papi A, Ison MG, Langley JM, Lee DG, Leroux-Roels I, Martinon-Torres F, Schwarz TF, van Zyl-Smit RN, Campora L, Dezutter N, de Schrevel N, Fissette L, David MP, Van der Wielen M, Kostanyan L, and Hulstrøm V
- Subjects
- Aged, Humans, Adjuvants, Immunologic administration & dosage, Adjuvants, Immunologic adverse effects, Adjuvants, Immunologic therapeutic use, Antibodies, Viral, Internationality, Vaccine Efficacy, Respiratory Syncytial Virus Infections epidemiology, Respiratory Syncytial Virus Infections prevention & control, Respiratory Syncytial Virus Vaccines administration & dosage, Respiratory Syncytial Virus Vaccines adverse effects, Respiratory Syncytial Virus Vaccines therapeutic use, Respiratory Syncytial Virus, Human, Respiratory Tract Infections epidemiology, Respiratory Tract Infections prevention & control
- Abstract
Background: Respiratory syncytial virus (RSV) is an important cause of acute respiratory infection, lower respiratory tract disease, clinical complications, and death in older adults. There is currently no licensed vaccine against RSV infection., Methods: In an ongoing, international, placebo-controlled, phase 3 trial, we randomly assigned, in a 1:1 ratio, adults 60 years of age or older to receive a single dose of an AS01
E -adjuvanted RSV prefusion F protein-based candidate vaccine (RSVPreF3 OA) or placebo before the RSV season. The primary objective was to show vaccine efficacy of one dose of the RSVPreF3 OA vaccine against RSV-related lower respiratory tract disease, confirmed by reverse-transcriptase polymerase chain reaction (RT-PCR), during one RSV season. The criterion for meeting the primary objective was a lower limit of the confidence interval around the efficacy estimate of more than 20%. Efficacy against severe RSV-related lower respiratory tract disease and RSV-related acute respiratory infection was assessed, and analyses according to RSV subtype (A and B) were performed. Safety was evaluated., Results: A total of 24,966 participants received one dose of the RSVPreF3 OA vaccine (12,467 participants) or placebo (12,499). Over a median follow-up of 6.7 months, vaccine efficacy against RT-PCR-confirmed RSV-related lower respiratory tract disease was 82.6% (96.95% confidence interval [CI], 57.9 to 94.1), with 7 cases (1.0 per 1000 participant-years) in the vaccine group and 40 cases (5.8 per 1000 participant-years) in the placebo group. Vaccine efficacy was 94.1% (95% CI, 62.4 to 99.9) against severe RSV-related lower respiratory tract disease (assessed on the basis of clinical signs or by the investigator) and 71.7% (95% CI, 56.2 to 82.3) against RSV-related acute respiratory infection. Vaccine efficacy was similar against the RSV A and B subtypes (for RSV-related lower respiratory tract disease: 84.6% and 80.9%, respectively; for RSV-related acute respiratory infection: 71.9% and 70.6%, respectively). High vaccine efficacy was observed in various age groups and in participants with coexisting conditions. The RSVPreF3 OA vaccine was more reactogenic than placebo, but most adverse events for which reports were solicited were transient, with mild-to-moderate severity. The incidences of serious adverse events and potential immune-mediated diseases were similar in the two groups., Conclusions: A single dose of the RSVPreF3 OA vaccine had an acceptable safety profile and prevented RSV-related acute respiratory infection and lower respiratory tract disease and severe RSV-related lower respiratory tract disease in adults 60 years of age or older, regardless of RSV subtype and the presence of underlying coexisting conditions. (Funded by GlaxoSmithKline Biologicals; AReSVi-006 ClinicalTrials.gov number, NCT04886596.)., (Copyright © 2023 Massachusetts Medical Society.)- Published
- 2023
- Full Text
- View/download PDF
42. Three Dose Levels of a Maternal Respiratory Syncytial Virus Vaccine Candidate Are Well Tolerated and Immunogenic in a Randomized Trial in Nonpregnant Women.
- Author
-
Schwarz TF, Johnson C, Grigat C, Apter D, Csonka P, Lindblad N, Nguyen TL, Gao FF, Qian H, Tullio AN, Dieussaert I, Picciolato M, and Henry O
- Subjects
- Antibodies, Neutralizing, Antibodies, Viral, Female, Humans, Infant, Pregnancy, Viral Fusion Proteins, Respiratory Syncytial Virus Infections, Respiratory Syncytial Virus Vaccines, Respiratory Syncytial Virus, Human
- Abstract
Background: Respiratory syncytial virus (RSV) causes respiratory tract infections, which may require hospitalization especially in early infancy. Transplacental transfer of RSV antibodies could confer protection to infants in their first months of life., Methods: In this first-in-human, placebo-controlled study, 502 healthy nonpregnant women were randomized 1:1:1:1 to receive a single dose of unadjuvanted vaccine containing 30/60/120 µg of RSV fusion (F) protein stabilized in the prefusion conformation (RSVPreF3) or placebo., Results: Solicited local adverse events (AEs) were more frequently reported in the RSVPreF3 groups (4%-53.2%) versus placebo (0%-15.9%); most were mild/moderate. Unsolicited AEs were comparably reported among groups. Three serious AEs were reported; none was vaccination-related. Compared with prevaccination values, anti-RSV A neutralizing antibody geometric mean titers and anti-RSVPreF3 immunoglobulin G geometric mean concentrations increased 8- to 14-fold and 12- to 21-fold at day 8 and persisted 5- to 6-fold and 6- to 8-fold higher until day 91 in the RSVPreF3 groups versus 1-fold in placebo. Comparisons at day 8 and day 31 showed that the higher dose levels were significantly more immunogenic than the lowest one., Conclusions: The RSVPreF3 vaccine was well tolerated and immunogenic. The 60 and 120 µg dose levels were selected for further investigation in pregnant women., Clinical Trials Registration: NCT03674177., (© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America.)
- Published
- 2022
- Full Text
- View/download PDF
43. Importance and value of adjuvanted influenza vaccine in the care of older adults from a European perspective - A systematic review of recently published literature on real-world data.
- Author
-
Gärtner BC, Weinke T, Wahle K, Kwetkat A, Beier D, Schmidt KJ, and Schwarz TF
- Subjects
- Adjuvants, Immunologic, Aged, Humans, Polysorbates, Squalene, Influenza Vaccines, Influenza, Human prevention & control
- Abstract
Background: There is an urgent need for improved influenza vaccines especially for older adults due to the presence of immunosenescence. It is therefore highly relevant to compare enhanced influenza vaccines with traditional influenza vaccines with respect to their effectiveness., Objective: To compare vaccine efficacy and effectiveness of adjuvanted influenza vaccines (aTIV/aQIV) vs. non-adjuvanted standard-dose (TIV/QIV) and high-dose (TIV-HD/QIV-HD) influenza vaccines regarding influenza-related outcomes in older adults, complementing findings from the European Centre for Disease Prevention and Control (ECDC)'s systematic review of enhanced seasonal influenza vaccines from February 2020., Methods: A systematic literature search was conducted in Embase and MEDLINE to identify randomised controlled trials, observational studies and systematic reviews, published since ECDC's systematic review (between 7 February 2020 and 6 September 2021). Included studies were appraised with either the Cochrane Risk of Bias tool, ROBINS-I or AMSTAR 2., Results: Eleven analyses from nine real-world evidence (RWE) studies comprising ∼53 million participants and assessing the relative vaccine effectiveness (rVE) of aTIV vs. TIV, QIV and/or TIV-HD in adults aged ≥65 years over the 2006/07-2008/09 and 2011/12-2019/20 influenza seasons were identified. Nine analyses found that aTIV was significantly more effective than TIV and QIV in reducing influenza-related outcomes by clinical setting and suspected influenza outbreaks (rVE ranging from 7.5% to 25.6% for aTIV vs. TIV and 7.1% to 36.3% for aTIV vs. QIV). Seven analyses found similar effectiveness of aTIV vs. TIV-HD in reducing influenza-related medical encounters, inpatient stays and hospitalisations/emergency room visits. In three analyses, aTIV was significantly more effective than TIV-HD in reducing influenza-related medical encounters and office visits (rVE ranging from 6.6% to 16.6%). Risk of bias of identified studies was moderate to high., Conclusions: Our study suggests that both adjuvanted and high-dose vaccines are effective alternatives for vaccination programmes in older adults and preferable over conventional standard-dose vaccines., Competing Interests: Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: TW, KW, AK, DB and TFS have received honoraria from Seqirus GmbH for their contribution to this work. KJS was employed by Xcenda GmbH which received funding from Seqirus GmbH., (Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
44. A new fully liquid presentation of MenACWY-CRM conjugate vaccine: Results from a multicentre, randomised, controlled, observer-blind study.
- Author
-
Vandermeulen C, Leroux-Roels I, Vandeleur J, Staniscia T, Girard G, Ferguson M, Icardi G, Schwarz TF, Neville AM, Nolan T, Cinquetti S, Akhund T, Van Huyneghem S, Aggravi M, Kunnel B, de Wergifosse B, Domenico GFD, Costantini M, Vir Singh P, Fragapane E, Lattanzi M, and Pellegrini M
- Subjects
- Adult, Antibodies, Bacterial, Humans, Vaccination, Vaccines, Conjugate, Meningococcal Infections, Meningococcal Vaccines
- Abstract
Background: The currently licensed quadrivalent MenACWY-CRM conjugate vaccine presentation consists of two vials (lyophilised MenA and liquid MenCWY) to be reconstituted before injection. A new fully liquid formulation in a single vial has been developed to further improve the vaccine presentation. Since the MenA structure is subject to hydrolytic degradation, this study was conducted to compare the immunogenicity and safety of the investigational MenACWY-CRM liquid vaccine with the licensed vaccine., Methods: In this multicentre, randomised, controlled, observer-blind, phase 2b study, 979 healthy adults were administered a single dose of MenACWY-CRM liquid presentation or the currently licensed MenACWY-CRM vaccine. MenA free saccharide generation was accelerated to approximately 30% in the liquid presentation and MenA polysaccharide O-acetylation was reduced to approximately 40%, according to a controlled procedure. Immunological non-inferiority of the MenACWY-CRM liquid to the licensed vaccine, as measured by human serum bactericidal assay (hSBA) geometric mean titres (GMTs) against MenA 1 month post-vaccination, was the primary study objective. Safety assessment was among the secondary objectives., Results: Immune responses against each serogroup were similar between the two vaccine groups and was non-inferior for MenA. Adjusted hSBA GMTs for MenA were 185.16 and 211.33 for the MenACWY-CRM liquid presentation and currently licensed vaccine presentation, respectively. The between-group ratio of hSBA GMTs for MenA was 0.88, with a two-sided 95% confidence interval lower limit of 0.64, greater than the prespecified non-inferiority margin of 0.5, thus meeting the primary study objective. Both vaccines were well tolerated. No serious adverse events were considered related to vaccination., Conclusions: The levels of MenA free saccharide and polysaccharide O-acetylation did not affect the immunogenicity of the fully liquid presentation, which was demonstrated to be non-inferior to the immunogenicity of the currently licensed MenACWY-CRM vaccine against MenA. The immunogenicity, reactogenicity and safety profiles of the two vaccine presentations were similar., Competing Interests: Declaration of Competing Interest TA, SVH, MA, BK, BdW, GFDD, MC, PVS, EF, ML and MP are employed by the GSK group of companies. TA, MA, BdW, PVS, EF, ML and MP hold shares in the GSK group of companies. CV reports her institution received payments from the GSK group of companies, MSD and Pfizer, outside the submitted work. ILR reports her institution received payments from the GSK group of companies for the conduct of the study. TN reports payments from the GSK group of companies, Merck, Sanofi Pasteur and Seqirus, outside the submitted work. TA, SVH, MA, BK, BdW, GFDD, MC, PVS, EF, ML, MP, CV, ILR and TN declare no other financial and non-financial relationships and activities. JV, TS, GG, MF, GI, TFS, AMN and SC declare no financial and non-financial relationships and activities and no conflicts of interest., (Copyright © 2021 GlaxoSmithKline Biologicals S.A. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
45. Immunogenicity and Safety of 3 Formulations of a Respiratory Syncytial Virus Candidate Vaccine in Nonpregnant Women: A Phase 2, Randomized Trial.
- Author
-
Schwarz TF, McPhee RA, Launay O, Leroux-Roels G, Talli J, Picciolato M, Gao F, Cai R, Nguyen TL, Dieussaert I, Miller JM, and Schmidt AC
- Subjects
- Adolescent, Adult, Antibodies, Neutralizing blood, Antibodies, Viral blood, Drug-Related Side Effects and Adverse Reactions epidemiology, Drug-Related Side Effects and Adverse Reactions pathology, Female, Healthy Volunteers, Humans, Injections, Intramuscular, Middle Aged, Placebos administration & dosage, Respiratory Syncytial Virus Vaccines administration & dosage, Vaccines, Subunit administration & dosage, Vaccines, Subunit adverse effects, Vaccines, Subunit immunology, Vaccines, Synthetic administration & dosage, Vaccines, Synthetic adverse effects, Vaccines, Synthetic immunology, Young Adult, Respiratory Syncytial Virus Infections prevention & control, Respiratory Syncytial Virus Vaccines adverse effects, Respiratory Syncytial Virus Vaccines immunology, Viral Fusion Proteins immunology
- Abstract
Background: Respiratory syncytial virus (RSV) is a common cause of respiratory tract illness and hospitalization in neonates and infants. RSV vaccination during pregnancy may protect offspring in their first months of life., Methods: This randomized, observer-blind, multicenter, phase 2 study evaluated the immunogenicity and safety of an RSV candidate vaccine in healthy nonpregnant women aged 18-45 years. Four hundred participants were randomized (1:1:1:1) to receive a single intramuscular dose of vaccine containing 30 µg, 60 µg, or 120 µg of RSV fusion protein engineered to preferentially maintain a prefusion conformation (RSV-PreF vaccine) or placebo., Results: Thirty days postvaccination, RSV-A neutralizing antibody geometric mean titers (GMTs) increased 3.75-, 4.42- and 4.36-fold; RSV-B neutralizing antibody GMTs 2.36-, 2.54- and 2.76-fold; and palivizumab competing antibody (PCA) concentrations 11.69-, 14.38- and 14.24-fold compared with baseline levels in the 30 µg, 60 µg, and 120 µg RSV-PreF groups, respectively. Antibody titers and PCA concentrations at day 30 were significantly higher with the 120 µg compared to the 30 µg RSV-PreF vaccine. All RSV-PreF vaccine formulations and the placebo had similar reactogenicity profiles. No serious adverse events were considered to be related to the RSV-PreF vaccine., Conclusions: The 3 formulations of the investigational RSV-PreF vaccine were well-tolerated and induced RSV-A and RSV-B neutralizing antibodies and PCAs in healthy, nonpregnant women., Clinical Trials Registration: NCT02956837., (© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.)
- Published
- 2019
- Full Text
- View/download PDF
46. Long-term Cross-reactivity Against Nonvaccine Human Papillomavirus Types 31 and 45 After 2- or 3-Dose Schedules of the AS04-Adjuvanted Human HPV-16/18 Vaccine.
- Author
-
Folschweiller N, Behre U, Dionne M, Durando P, Esposito S, Ferguson L, Ferguson M, Hillemanns P, McNeil SA, Peters K, Ramjattan B, Schwarz TF, Supparatpinyo K, Suryakirian PV, Janssens M, Moris P, Decreux A, Poncelet S, and Struyf F
- Subjects
- Adolescent, Adult, Antibodies, Viral immunology, B-Lymphocytes immunology, CD4-Positive T-Lymphocytes immunology, Child, Female, Humans, Immunization Schedule, Papillomavirus Infections virology, Vaccination methods, Young Adult, Adjuvants, Immunologic administration & dosage, Cross Reactions immunology, Papillomaviridae immunology, Papillomavirus Infections immunology, Papillomavirus Vaccines immunology
- Abstract
This analysis focused on long-term cross-reactive immunogenicity against nonvaccine human papillomavirus (HPV) types 31 and 45 following 2 doses of AS04-adjuvanted HPV-16/18 vaccine in girls aged 9-14 years or following 3 doses in women aged 15-25 years, for up to 3 years (HPV-070 study) and up to 5 years (HPV-048 study) after the first vaccination. Both schedules elicited antibodies against HPV-31 and HPV-45 up to 5 years after first dose. The antibody concentration was similar in young girls as compared to women. Specific CD4+ T-cell and B-cell responses to HPV-31 and HPV-45 at month 36 were similar across groups. Clinical trials registration: NCT01381575 and NCT00541970., (© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America.)
- Published
- 2019
- Full Text
- View/download PDF
47. A ten-year study of immunogenicity and safety of the AS04-HPV-16/18 vaccine in adolescent girls aged 10-14 years.
- Author
-
Schwarz TF, Huang LM, Valencia A, Panzer F, Chiu CH, Decreux A, Poncelet S, Karkada N, Folschweiller N, Lin L, Dubin G, and Struyf F
- Subjects
- Adjuvants, Immunologic administration & dosage, Adolescent, Child, Female, Follow-Up Studies, Humans, Papillomavirus Vaccines administration & dosage, Papillomavirus Vaccines adverse effects, Time Factors, Uterine Cervical Neoplasms prevention & control, Vaccination, Antibodies, Viral blood, Human papillomavirus 16 immunology, Human papillomavirus 18 immunology, Immunogenicity, Vaccine, Papillomavirus Infections prevention & control, Papillomavirus Vaccines immunology
- Abstract
This study assessed long-term immunogenicity and safety following 3 doses of AS04-adjuvanted human papillomavirus (HPV)-16/18 L1 virus-like particle (VLP) vaccine in females 10-14 years old. Girls included in the immunogenicity subset in the primary controlled, observer-blinded, randomized study (NCT00196924) who received 3 doses were invited for a 10-year follow-up (NCT00316706 and NCT00877877). Serum antibody responses against HPV-16/18 (vaccine types) and HPV-31/45 (non-vaccine types) were measured by enzyme-linked immunosorbent assay (ELISA) using type-specific VLP as coating antigens. Serious adverse events (SAEs) and pregnancy information were recorded. At Month (M) 120, all subjects (N = 418, according-to-protocol immunogenicity cohort) were seropositive for anti-HPV-16/18 antibodies. Geometric mean titers (GMTs) were 1589.9 ELISA Units [EU]/mL (95% confidence interval [CI]: 1459.8-1731.6) for anti-HPV-16 and 597.2 EU/mL (95% CI: 541.7-658.5) for anti-HPV-18 in subjects seronegative at baseline for the type analyzed. Post hoc mathematical modeling predicted a durability ≥50 years for anti-HPV-16 and anti-HPV-18. For the non-vaccine humoral type response, all initially seronegative subjects had seroconverted at M7, with anti-HPV-31 GMT of 2030.5 EU/mL (95% CI: 1766.2-2334.4) and anti-HPV-45 GMT of 2300.8 EU/mL (95% CI: 2036.8-2599.0). At M120, 87.7% and 85.1% remained seropositive for anti-HPV-31 with GMT of 242.9 EU/mL (95% CI: 201.4-293.0) and anti-HPV-45 with GMT of 204.7 EU/mL (95% CI: 170.0-246.6). During the 10-year follow-up, no SAEs or abnormal pregnancy outcomes were causally related to vaccination. Three doses of the AS04-HPV-16/18 vaccine induced high and sustained antibody response against HPV-16,18,31 and 45 in girls aged 10-14 years during the 10-year follow-up, with an acceptable long-term safety profile.
- Published
- 2019
- Full Text
- View/download PDF
48. Long-term antibody persistence against hepatitis B in adolescents 14-15-years of age vaccinated with 4 doses of hexavalent DTPa-HBV-IPV/Hib vaccine in infancy.
- Author
-
Schwarz TF, Behre U, Adelt T, Donner M, Suryakiran PV, Janssens W, Mesaros N, and Panzer F
- Subjects
- Adolescent, Antibodies, Bacterial blood, Diphtheria-Tetanus-Pertussis Vaccine administration & dosage, Female, Haemophilus Vaccines administration & dosage, Hepatitis B immunology, Hepatitis B Surface Antigens immunology, Hepatitis B Vaccines administration & dosage, Humans, Immunization Schedule, Infant, Infant, Newborn, Male, Poliovirus Vaccine, Inactivated administration & dosage, Time Factors, Vaccination statistics & numerical data, Vaccines, Combined administration & dosage, Vaccines, Combined immunology, Diphtheria-Tetanus-Pertussis Vaccine immunology, Haemophilus Vaccines immunology, Hepatitis B prevention & control, Hepatitis B Antibodies blood, Hepatitis B Vaccines immunology, Immunologic Memory, Poliovirus Vaccine, Inactivated immunology
- Abstract
We evaluated antibody persistence against hepatitis B virus (HBV) in adolescents previously vaccinated with a hexavalent diphtheria-tetanus-acellular pertussis-HBV-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine (DTPa-HBV-IPV/Hib), as part of the national newborn immunization program in Germany. We also assessed the anamnestic response to a challenge dose of a monovalent HBV vaccine. In this phase 4, open-label, non-randomized study (NCT02798952), 302 adolescents aged 14-15 years, primed in their first 2 years of life with 4 DTPa-HBV-IPV/Hib doses, received one challenge dose of monovalent HBV vaccine. Blood samples were taken before and one month post-vaccination and used to determine antibody levels against hepatitis B surface antigen (HBs). Reactogenicity and safety were also assessed post-challenge dose. Pre-challenge dose, 53.7% of 268 participants included in the according-to-protocol cohort for immunogenicity had anti-HBs antibody concentrations ≥10 mIU/mL (seroprotection cut-off) and 16.8% had anti-HBs antibody concentrations ≥100 mIU/mL. One month post-challenge dose, 93.3% of adolescents had anti-HBs antibody concentrations ≥10 mIU/mL and 87.3% had antibody concentrations ≥100 mIU/mL. An anamnestic response was mounted in 92.5% of adolescents. Injection site pain (in 33.6% of participants) and fatigue (30.2%) were the most frequently reported solicited local and general symptoms, respectively. Six of the 55 unsolicited adverse events reported were considered vaccination-related. Two vaccination-unrelated serious adverse events were reported during the study. Long-term antibody persistence against hepatitis B was observed in 14-15 years old adolescents previously primed in infancy with DTPa-HBV-IPV/Hib. A challenge dose of monovalent HBV vaccine induced strong anamnestic response, with no safety concerns.
- Published
- 2019
- Full Text
- View/download PDF
49. Immunogenicity and safety of the quadrivalent meningococcal vaccine MenACWY-TT co-administered with a combined diphtheria-tetanus-acellular pertussis vaccine versus their separate administration in adolescents and young adults: A phase III, randomized study.
- Author
-
Rivera L, Schwarz TF, Kim KH, Kim YK, Behre U, Cha SH, Jo DS, Lee J, Lee JS, Cheuvart B, Jastorff A, and Van der Wielen M
- Subjects
- Adolescent, Adult, Antibodies, Bacterial blood, Antigens, Bacterial immunology, Blood Bactericidal Activity, Child, Diphtheria-Tetanus-acellular Pertussis Vaccines administration & dosage, Drug-Related Side Effects and Adverse Reactions epidemiology, Drug-Related Side Effects and Adverse Reactions pathology, Enzyme-Linked Immunosorbent Assay, Humans, Meningococcal Vaccines administration & dosage, Single-Blind Method, Young Adult, Diphtheria-Tetanus-acellular Pertussis Vaccines adverse effects, Diphtheria-Tetanus-acellular Pertussis Vaccines immunology, Immunization Schedule, Meningococcal Vaccines adverse effects, Meningococcal Vaccines immunology
- Abstract
Background: This study evaluated the immunogenicity and safety of quadrivalent meningococcal conjugate vaccine using tetanus (T) toxoid as carrier protein (MenACWY-TT) co-administered with combined diphtheria-tetanus-acellular pertussis vaccine (Tdap) versus their separate administration in adolescents and young adults., Methods: In this phase III, randomized, partially-blind study (NCT01767376), healthy 11-25-year-olds (N = 660) were randomized (1:1:1) to receive MenACWY-TT and Tdap at Month 0 (Co-ad group), MenACWY-TT at Month 0 and Tdap at Month 1 (ACWY_Tdap group) or Tdap at Month 0 and MenACWY-TT at Month 1 (Tdap_ACWY group). Immune responses to MenACWY-TT were measured by serum bactericidal assay using rabbit complement (rSBA). Anti-diphtheria (D), anti-tetanus (T), anti-pertussis toxin (PT), anti-filamentous hemagglutinin (FHA) and anti-pertactin (PRN) antibody concentrations were assessed using enzyme-linked immunosorbent assays. Non-inferiority of immunogenicity was assessed using pre-defined clinical criteria. Safety was also evaluated., Results: Non-inferiority of immunogenicity of MenACWY-TT and Tdap when co-administered versus their separate administration was demonstrated in terms of rSBA geometric mean titers (GMTs) for 4 meningococcal serogroups and of the percentage of participants with antibody concentrations >1 IU/ml for D and T. Among the pertussis antigens, non-inferiority criteria for geometric mean concentrations (GMCs) were reached for PT, but not met for FHA and PRN. Across all groups, ≥93.2% of participants had vaccine responses to each meningococcal serogroup, ≥99.1% were seroprotected against T and D, and ≥85.5% had booster responses to each pertussis antigen. Robust increases in antibody GMTs/GMCs were observed for all antigens between pre-and post-vaccination. Both vaccines had clinically acceptable safety profiles., Conclusion: Immune responses to MenACWY-TT and to the T and D antigens from Tdap were not impacted by their co-administration. The lower antibody concentrations observed against the pertussis components may be of limited clinical relevance since robust anti-pertussis booster responses were observed. This study supports concurrent administration of the 2 vaccines in adolescents., (Copyright © 2018 GlaxoSmithKline Biologicals SA. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
50. Persistence of immune response to an adjuvanted varicella-zoster virus subunit vaccine for up to year nine in older adults.
- Author
-
Schwarz TF, Volpe S, Catteau G, Chlibek R, David MP, Richardus JH, Lal H, Oostvogels L, Pauksens K, Ravault S, Rombo L, Sonder G, Smetana J, Heineman T, and Bastidas A
- Subjects
- Adult, Aged, Aged, 80 and over, Cohort Studies, Cytokines analysis, Follow-Up Studies, Herpes Zoster Vaccine administration & dosage, Humans, Lipid A administration & dosage, Middle Aged, Time Factors, Vaccines, Subunit administration & dosage, Vaccines, Subunit immunology, Antibodies, Viral blood, Herpes Zoster Vaccine immunology, Herpesvirus 3, Human immunology, Lipid A analogs & derivatives, Saponins administration & dosage, T-Lymphocytes immunology
- Abstract
Background: In adults aged ≥60 years, two doses of the herpes zoster subunit vaccine (HZ/su; 50 µg varicella-zoster virus glycoprotein E [gE] and AS01
B Adjuvant System) elicited humoral and cell-mediated immune responses persisting for at least six years. We assessed immunogenicity nine years post-initial vaccination., Methods: This open extension study (NCT02735915) followed 70 participants who received two HZ/su doses in the initial trial (NCT00434577). Blood samples to assess the cellular (intracellular cytokine staining) and humoral (ELISA) immunity were taken at year nine post-initial vaccination., Results: Participants' mean age at dose 1 was 72.3 years. The fold increases over pre-vaccination in the mean frequency of gE-specific CD4+ T-cells expressing ≥2 activation markers plateaued from year four post-dose 1 until year nine. Anti-gE antibody geometric mean concentrations plateaued and remained above pre-vaccination levels from year four onwards. Immunogenicity at year nine was similar across age strata (60-69, ≥70 years) and confirmed statistical prediction model results using data for up to year six. Further modeling using all data up to year nine predicted immune responses would remain above the pre-vaccination level up to year 15., Conclusion: In adults aged ≥60 years, HZ/su-induced immunogenicity remained above pre-vaccination levels for at least nine years post-initial vaccination., Summary: After vaccination with HZ/su, both cell mediated and humoral immunity remained above pre-vaccination levels up to year 9 regardless of age group. Immune responses are predicted to remain above baseline up to 15 years post initial vaccination.- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.